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Resumo 
 
 
A Farmacogenética dedica-se ao estudo da influência das variações genéticas 
humanas na resposta às drogas, e ao longo do tempo tem vindo a adquirir uma 
importância crescente na prática clínica, com a promessa de tratamentos mais 
personalizados, que maximizem a eficiência da droga e minimizem a ocorrência de 
reações de toxicidade. Muitos genes têm sido estudados no campo da 
farmacogenética, desde genes codificadores de enzimas metabolizadoras, alvos e 
transportadores das drogas, a fim de compreender o seu papel na variação da 
resposta às drogas. 
Embora muitas populações já tenham sido investigadas em estudos 
farmacogenéticos, existem ainda populações pouco estudadas neste contexto, como 
são exemplo os Ciganos da Europa. Devido à sua história e estilo de vida, vivendo em 
pequenos grupos endogâmicos, os Ciganos têm peculiaridades genéticas únicas, que 
os tornam em interessantes casos de estudo. 
O objetivo principal deste trabalho consistiu em caracterizar uma amostra de 
Ciganos Portugueses para uma serie de SNPs selecionados, localizados em genes 
com importância farmacogenética e comparar o perfil farmacogenético obtido nesta 
população, com o perfil da população hospedeira Portuguesa. Neste sentido, uma 
amostra de 116 Ciganos Portugueses foi genotipada recorrendo ao sistema de PCR 
multiplex, desenhado e otimizado para detetar 10 polimorfismos, localizados em 5 
genes, conhecidos por influenciar a resposta as drogas: CYP2C9 e CYP2C19 que 
codificam enzimas com importância na fase I do metabolismo das drogas; TPMT e 
NAT2 que codificam enzimas intervenientes na fase II do metabolismo e VKORC1 que 
codifica um alvo das drogas. Além desta população foi também genotipado um grupo 
controlo de 70 Portugueses não Ciganos para realizar análises comparativas. Os 
resultados obtidos para estas duas populações foram comparados com dados 
anteriormente publicados para várias populações do mundo a fim de avaliar o padrão 
global de distribuição das frequências. 
 Para as variações selecionadas não foram detetados desvios ao equilíbrio de 
Hardy-Weinberg tanto na população Portuguesa Cigana como na População 
Portuguesa não Cigana e, comparando os resultados das duas populações não foram 
detetadas diferenças significativas. Contudo, como apenas um pequeno grupo de 
SNPs foi analisado, mais estudos são necessários para explorar a existência de 
variações adicionais que possam ter um impacto substancial na resposta a drogas nos 
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indivíduos Ciganos, embora estas sejam irrelevantes (por serem ausentes ou raras) 
noutros Portugueses. 
O presente estudo contribuiu assim para enriquecer a caracterização dos grupos 
ciganos, abrindo portas para uma melhor compreensão destes grupos populacionais 
no contexto farmacogenético.     
 
Palavras-Chave: Farmacogenética; População Cigana; Metabolismo das drogas; Alvo 
das drogas. 
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Abstract 
 
 
Pharmacogenetics is dedicated to the study of the influence of human genetic 
variations in the drug response and along the time has been acquired an increasing 
importance in the clinical practice with the promise of more personalised drug 
treatments that maximises the drug efficacy and minimises the drug toxicity. Many 
genes have been studied in the field of pharmacogenetics, since drug metabolising 
enzymes to drug targets and drug transporters, in order to understand their role in 
variation of drug response. 
Although many populations have already been investigated in pharmacogenetic 
studies, there are still populations scarcely studied in this context, such as the Gypsies 
from Europe. Due to their history and life style, living in small endogamous groups, the 
Roma have unique genetic peculiarities, making them an interesting case study. 
The main goal of the present work was to characterise a sample of Portuguese 
Gypsies for a selected battery of SNPs in genes with pharmacogenetic relevance, and 
to compare the derived pharmacogenetic profile with that of the Portuguese host 
population. Viewing this, a sample of 116 Portuguese Gypsies was typed with a PCR 
multiplex system, designed and optimised to detect 10 SNPs located in 5 genes known 
to influence the response to drugs: CYP2C9 and CYP2C19 that encode important 
enzymes of the phase I of the drug metabolism; TPMT and NAT2 that codify relevant 
enzymes that intervene in phase II of the drug metabolism and VKORC1 that codify a 
drug target. In addition, to perform comparative analyses, a control group of 70 
Portuguese non-Gypsy individuals was also genotyped. The results obtained for these 
two populations were compared with previously published data for several populations 
around the world, in order to assess global patterns of frequencies distribution. 
For the screened variations no departures from Hardy-Weinberg equilibrium were 
detected in the Portuguese Gypsy and Portuguese non-Gyspy populations. Comparing 
the results of the two populations no major differences were detected. However, as 
only a small group of SNPs was analysed, further studies are needed to explore 
whether additional variations apart from those examined might impact substantially 
drug response in Gypsies, whilst being irrelevant (due to absence or rarity) in other 
Portuguese. 
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The present study has contributed to deepen the characterisation of Gypsy 
communities, opening new doors to achieve a better knowledge of these population 
groups in the pharmacogenetic context. 
 
Keywords: Pharmacogenetics; Gypsy population; SNP; Drug metabolism; Drug targets. 
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I. INTRODUTION 
 
 
1. Pharmacogenetics 
 
Pharmacogenetics arose from the challenge of understanding how the genetic 
variations influence the different drug responses that many individuals present. In 510 
B.C., Pythagoras had already described that some individuals, after the ingestion of 
fava beans, manifested unusual reactions, today known as haemolytic anaemia, while 
others did not showed them (Kupiec et al., 2006; Pelotti and Bini, 2011). However, it 
was only in 1950 that was clearly documented the first association between inherited 
genetic information and variable drug response, leading to the acknowledgement of the 
Pharmacogenetics as a science (Evans and McLeod, 2003; Kalow, 2006; Lanfear and 
McLeod, 2007). 
Nowadays is well established that interindividual variation in drug disposition and 
effectiveness is in great part due to genetic factors, while non-genetic factors such as 
age, gender, co-medication or even the nature of the disease may also contribute to 
variability in drug response (Evans and McLeod, 2003; Pilgrim et al., 2011). 
The genetic influence is mainly due to the presence of variations in DNA sequence, 
known as genetic polymorphisms when the frequency of the minor allele is ≥ 1% in a 
population. In the human genome, the single nucleotide polymorphisms (SNPs) are the 
most common source of genetic polymorphisms accounting for approximately 90% of 
all genetic variations. The SNPs result from changes in single nucleotides of the DNA 
sequence that sometimes can lead to the alteration of the encoded protein, as well as 
to the alteration in the quantity of protein expressed, depending on the nucleotide 
changed and its location (Lanfear and McLeod, 2007; Kudzi et al., 2011; Pilgrim et al., 
2011). 
When genetic polymorphisms occur in genes that encode enzymes responsible for 
the absorption, distribution, metabolism or excretion of drugs, such as drug 
metabolising enzymes, drug transporters and drug targets, that can lead to the 
alteration of kinetics and dynamics of drugs in the human organism, thus causing 
variability in drug responses (Evans and McLeod, 2003; Weinshilboum and Wang, 
2006; Pilgrim et al., 2011). It is on these processes that Pharmacogenetics 
concentrates its efforts, trying to understand how genetic polymorphisms affect either 
pharmacokinetics or pharmacodynamics of drugs. Indeed, given that pharmacokinetics 
comprehends the pathways that a drug takes through the organism, from absorption, to 
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metabolism and excretion, whereas pharmacodynamics respect to how drugs interact 
with receptors to initiate the drug response, it is understandable that both dynamics can 
determine drug effects and responses (Johnson, 2003; Weinshilboum and Wang, 
2004; Weinshilboum and Wang, 2006) (Figure 1). 
  
  
 
 
Figure 1. The functional components of Pharmacogenetics. The drug metabolising enzymes and drug transporters 
frequently influence the pharmacokinetics, while the drug targets commonly contribute for the variability in 
pharmacodynamics. The dashed line indicates that drug transporters are sometimes the drug targets. Adapted from 
Johnson, (2003). 
 
 
The information acquired through pharmacogenetic studies can be a useful tool in 
several areas such as the clinical practice and the forensic analysis, since it allows to 
improve the relation between patient and drug, avoiding unexpected results in 
therapeutic treatments and contributing to the interpretation of deaths that remain 
unclear (Pilgrim et al., 2011). In the following section these two subjects will be 
explored in more detail. 
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1.1 Pharmacogenetic applications 
 
As mentioned in the previous section it is frequent to observe that different patients 
may react differently to the same drug and dose: some develop adverse drug reactions 
(ADRs), which sometimes can be fatal, others react well or with rather efficacy to the 
treatment, while others do not even respond to the therapy. This variability of 
responses of individuals to a standardised treatment is a relevant question in clinical 
practice (Kudzi et al., 2011). The aim of Pharmacogenetics in the medical context is to 
identify polymorphisms in genes that can affect the effectiveness of a specific drug, 
diminishing the number of ADRs and treatment failure, therefore allowing the 
implementation of a more personalised, safe and effective therapy (Spear et al., 2001; 
Kalow, 2002; Fishbain et al., 2004; Kudzi et al., 2011). This rational administration of 
drugs is not only beneficial for patients, but also allows the reduction of healthcare 
costs (Rai et al., 2009). Furthermore, Pharmacogenetics can also play a key role in the 
development of new drugs, which can be safer if taking into account the genetic 
information (Daly, 2010).  
The recent developments in Pharmacogenetics knowledge have also given an 
important contribution to the forensic area given its role in the interpretation of 
circumstances of deaths. Through Pharmacogenetic studies it is possible to provide 
information about the metabolic capacity of individuals and potential drug outcomes, 
that can help the evaluation of post-mortem toxicology results and the determination of 
the involvement of a drug in the death (Pilgrim et al., 2011). That explains why the 
recruitment of pharmacogenetic data has allowed the clarification, in collaboration with 
information from the autopsy, clinical history and investigation of the death scene, of 
the cause and manner of death (Wong et al., 2003; Kupiec et al., 2006; Musshoff et al., 
2010). 
In particular situations, in which the circumstances of death are difficult to interpret 
due to non-existence of evidence of trauma or to ambiguous autopsy results, the 
pharmacogenetic analysis can be a useful tool for the medico-legal investigations, 
since genetic information can offer an additional knowledge of a possible genetic 
mutation that predisposes the individual to risk conditions leading to death. For 
example, in cases that post-mortem toxicological reports indicate a fatal concentration 
of a particular drug, it is difficult to understand if the death was accidental or suicide. 
However, with further information of genetic analysis it can be possible to understand if 
the high concentration of the drug was due to a genetic defect of the individual, making 
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the cause of death accidental, or if it was due to a high intake, making the cause of 
death intentional (Sajantila et al., 2010). 
Thus, with the association of pharmacogenetic analysis with post-mortem 
toxicology it can be possible to have new insights into the cause and circumstances of 
death of an individual (Musshoff et al., 2010; Sajantila et al., 2010).Current challenges 
 
 
1.2 Current challenges 
 
Since the post-genomic era, that clinical application of the Pharmacogenetics 
appears as being a promise of a more personalized medicine, through the application 
of the genetic knowledge in the improvement of the drugs and dosages, making the 
drug administration more safe and efficient (Swen et al., 2007).  
Although over time, the knowledge of the role that the genes play in the drug 
responses has improved and with it have emerged several promising clinical 
pharmacogenetic tests, their application in patient care is still scarce. Many reasons 
have been appointed as the cause of this limited application, such as educational, 
financial, guidelines, social, legal and ethical barriers (Weinshilboum and Wang, 2004; 
Weinshilboum and Wang, 2006; Swen et al., 2007; Crews et al., 2012; Moaddeb and 
Haga, 2013). 
For implementation of a pharmacogenetic test in clinical practice it is required a 
strong scientific evidence that it will improve the clinical outcomes of the patients, 
otherwise its introduction in medical healthcare would not be beneficial (Weinshilboum 
and Wang, 2004; Swen et al., 2007; Swen and Guchelaar, 2012; Moaddeb and Haga, 
2013). 
The costs are other barrier to the integration of the Pharmacogenetics into routine 
clinical. The cost-effectiveness studies for these tests are an important determinant for 
their implementation since should demonstrate their clinical utility and validity and also 
prove capable of provide the return in investment to the payers (Scott, 2011; Swen and 
Guchelaar, 2012). Many recent studies that evaluate the clinical utility and validity of 
Pharmacogenetics tests have shown results that provide incentive for reimbursement 
of genetic testing and investment in implementation strategies (Crews et al., 2012). 
The education of all healthcare professionals, specially the physicians, about 
pharmacogenetic testing, influences strongly their implementation into clinical practice, 
since they are responsible for their prescription. Many studies have indicated that 
clinicians in general have not much confidence in pharmacogenetic services because 
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of insufficient training and knowledge. Due to the lack of these two skills it is difficult to 
the doctors to understand the clinical utility of the tests, how to get them and how to 
interpret and apply their results into the patients care (Weinshilboum and Wang, 2004; 
Woelderink et al., 2005; Scott, 2011; Crews et al., 2012; Swen and Guchelaar, 2012). 
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2. The drug metabolism 
 
During the course of our life the human body is exposed to an uncountable number 
of xenobiotics – foreign elements to the body. Xenobiotics can be food elements, 
environmental chemicals or even pharmaceuticals, which can cause diverse damages 
to the body. When these elements enter the organism, a complex of enzymatic 
mechanisms performs biochemical transformations that convert the components in 
other, less harmful, trying to minimise the aggression caused by xenobiotic substances 
(Liska, 1998; Rushmore and Kong, 2002; Gonzalez and Turkey, 2006; Taniguchi and 
Guengerich, 2012). The mechanism responsible for the biotransformation of 
xenobiotics is commonly referred to as drug metabolism or drug biotransformation. An 
essential part of the drug metabolism is the chain of biochemical reactions that 
transform the foreign elements in components easier to excrete, preventing its 
accumulation in the body and possible toxic reactions. These reactions are also 
capable to alter drugs or its precursors in four different forms: an active drug can be 
inactivated; an active drug can be altered into an active or toxic metabolite; an inactive 
prodrug can be converted into an active drug and an unexcretable drug can be 
metabolised into an excretable metabolite (Taniguchi and Guengerich, 2012). 
This mechanism of biotransformation of foreign chemicals involves several 
enzymes, denominated as drug metabolising enzymes or xenobiotic metabolising 
enzymes (DMEs or XMEs), which are responsible by a number of different steps in the 
biochemical reactions (Rushmore and Kong, 2002; Xu et al., 2005). 
While many tissues and organs are involved in drug metabolism, the liver is the 
principal organ of drug biotransformation, expressing, therefore, high levels of DMEs. 
When oral drugs are administrated, the liver metabolism is so efficient that only a small 
portion of drug passes to the blood circulation – first pass effect  (Stachulski and 
Lennard, 2000; Taniguchi and Guengerich, 2012) 
The drug metabolism consists in two main different phases. Phase I, that includes 
functionalisation reactions (mainly oxidation, hydroxylation, and hydrolysis) by adding 
or exposing a polar group, and phase II, in which occur conjugation reactions between 
a polar group, possibly originated in phase I, and endogenous substrates such as 
glucuronic acid, forming a water-soluble product easier to eliminate (Stachulski and 
Lennard, 2000). 
 Although phase I and II reactions can occur independently of one another, 
normally they occur sequentially. While these are the main phases of the drug 
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metabolism, references to a phase III can be found in the bibliography, associated with 
transport of drugs in the organism (Xu et al., 2005; Olinga et al., 2008).  
The rate of biotransformation reactions is not the same in all individuals, since it is 
frequent to observe interindividual differences in the metabolism due to factors such as 
age, gender, diet, drinking and smoking habits as well as to genetic profile (Pilgrim et 
al., 2011; Taniguchi and Guengerich, 2012).  
Up to now, about 30 gene families of DMEs were already described (Kudzi et al., 
2011; Pilgrim et al., 2011). 
 
 
2.1 Phase I of the drug metabolism 
 
The phase I of the drug metabolism is the first enzymatic defence that acts against 
foreign elements, including therapeutic drugs (Liska, 1998). Usually, the phase I 
enzymes catalyse several reactions such as oxidation, reduction, hydrolysis, cyclization 
and decyclization. These reactions frequently lead to the inactivation of the drug, but in 
some cases they can also bioactivate some drugs that are inactive, called prodrugs, or 
may even produce toxic molecules that can cause damage to the body if not posteriorly 
metabolised by phase II enzymes (Liska, 1998; Gonzalez and Turkey, 2006).  
Several DMEs are involved in these processes, like esterases, reductases, alcohol 
dehydrogenases and mainly the cytochrome P450 (CYP) superfamily (Tiwari et al., 
2009; Pilgrim et al., 2011). 
 
 
2.1.1 Cytochrome P450 system 
 
The CYP enzymes are a superfamily of heme-thiolate proteins responsible for the 
metabolism of a great number of endogenous molecules like steroids, fatty acids, 
prostaglandins, as well as exogenous agents, such as drugs and other xenobiotics 
(Danielson, 2002; Zanger et al., 2008). These enzymes are located primarily in the 
endoplasmic reticulum of liver cells, but also in extra-hepatic tissues such as lung, 
intestines and brain, and are responsible for about 80% of the phase I reactions 
(Ingelman-Sundberg et al., 2007; Pilgrim et al., 2011). 
The human genome comprises several functional CYP genes and some 
pseudogenes, divided in families and subfamilies according to the degree of similarity 
of their DNA sequence (Zanger et al., 2008). Each CYP isoenzyme is named according 
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to specific norms that can be illustrated using the example of CYP2C9: the cytochrome 
P450 designation is CYP, the family designation is indicated by an Arabic number 
(CYP2), the subfamily designation is characterised by a capital  letter (CYP2C) and the 
last number represents a particular gene (Poolsup et al., 2000; Ma et al., 2002). 
The CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2B6 and CYP1A2 enzymes have 
the most crucial role in the drug metabolism, biotransforming more than 90% of the 
CYP superfamily substrates. Some associations between drug response and genetic 
polymorphisms of these enzymes have been described, especially with polymorphisms 
of CYP2D6, CYP2C9 and CYP2C19 genes  (Hiratsuka et al., 2006).  
The polymorphic nature of these CYP enzymes leads to the emergence of 
differences in their metabolic activity, that correlates with four different phenotypes: the 
extensive metaboliser (EM) phenotype, when the individuals carry two functional 
alleles; poor metaboliser (PM) phenotype, when the individuals inherit two defective or 
deleted alleles; intermediate metaboliser (IM) phenotype, when the individuals inherit 
one functional and one defective allele or they inherit two partially defective alleles; and 
ultrarapid metaboliser (UM) phenotype, when more than two active genes are 
producing a particular CYP enzyme.  While the EM show a normal enzymatic activity, 
comparatively the PM and the UM phenotypes show a lower and a higher metabolic 
capacity, respectively. On the other hand, the IMs phenotypes show a metabolic 
capacity between PMs and EMs (Hiratsuka et al., 2006; Ingelman-Sundberg et al., 
2007). 
Depending on the type of phenotype that the individuals present, the drug 
metabolism can be variable, consequently affecting the drug effectiveness. As an 
example, when a prodrug is administrated to an individual with a PM phenotype, 
therapeutic failure can occur since his low metabolic capacity does not allow the 
expected bioactivation of the prodrug into an active drug (Musshoff et al., 2010; Pilgrim 
et al., 2011). 
 
 
2.1.1.1 Cytochrome P450 2C9 – CYP2C9 
 
The CYP2C9 is an important isoenzyme of the CYP complex that is mainly 
expressed in the human liver. It is involved in the metabolism of multiple drugs such as 
warfarin, tolbutamide and phenytoin as well as some endogenous substrates like 
arachidonic and linolenic acids (Ingelman-Sundberg et al., 2007; Cavallari et al., 2011). 
The warfarin, an oral anticoagulant widely used for prevention and treatment of 
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thromboembolism disorders, is one of the more well studied drugs in Pharmacogenetic 
fields, due to its narrow therapeutic window (Kwon et al., 2011). This drug exerts its 
pharmacologic effect by inhibiting the vitamin k epoxide reductase complex subunit 1 
(VKORC1), an important element in the formation of active clotting factors. Warfarin is 
a racemic mixture of S-warfarin and R-warfarin where the S-enantiomer is the more 
active compound and has a greater therapeutic effect (Saminathan et al., 2010; Lam 
and Cheung, 2012). The enantiomers of warfarin are metabolised by 2 different 
pathways. S-warfarin is mostly metabolised by CYP2C9 while R-warfarin is mainly 
metabolised by CYP1A2 and CYP3A4 (D’Andrea et al., 2008; Limdi and Veenstra, 
2008; Saminathan et al., 2010) (Figure 2). 
Once the more pharmacologically potent S-form of warfarin is mainly 
biotransformed by CYP2C9, it is expected that variations on CYP2C9 gene can 
contribute greatly for the large interindividual variability in warfarin response and  
dosage requirement (Rieder et al., 2005; D’Andrea et al., 2008; Limdi and Veenstra, 
2008). 
The CYP2C9, located on chromosome 10q24.2, is a polymorphic gene with many 
different allelic variants identified to date (http://www.cypalleles.ki.se/cyp2c9.htm) 
(Cavallari et al., 2011; Pilgrim et al., 2011). The CYP2C9*1, often designed as the wild-
type allele, encodes for a functional product associated to normal enzymatic activity, 
whereas CYP2C9*2 (rs1799853, c.430C>T, p.R144C) and CYP2C9*3 (rs1057910, 
c.1075A>C, p.I359L) have been identified as the most common reduction-function 
variants that have an important role in the warfarin metabolism (Pilgrim et al., 2011; 
Voora and Ginsburg, 2012). Although both conduct to the same metabolic phenotype, 
while CYP2C9*2 may cause a decrease of approximately 30% on enzymatic activity, 
CYP2C9*3 may lead to reductions of about 80% (Markatos et al., 2008; Kwon et al., 
2011).  
In the warfarin metabolism, the reduced activity of CYP2C9 leads to a decrease on 
clearance of S-warfarin and in the warfarin dose requirements, translating into about 
19% of dose reduction per allele for CYP2C9*2 and approximately 33% of dose 
reduction per allele for CYP2C9*3 compared to non-carriers. Furthermore, the 
diminished activity of CYP2C9 increases the risk of bleeding complications (Voora and 
Ginsburg, 2012). 
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Figure 2. The metabolic pathways of warfarin. The warfarin is a racemic mixture of S- and R-warfarin. While the S-
warfarin is mostly metabolised by CYP2C9, the R-warfarin is mainly metabolised by CYP3A4 and CYP1A2.     
 
 
2.1.1.2 Cytochrome P450 2C19 – CYP2C19 
 
The CYP2C19 isoenzyme is part of CYP2C subfamily alongside with the CYP2C8, 
CYP2C9 and CYP2C18 enzymes, being responsible for the metabolism of various 
therapeutic drugs such as omeprazole, diazepam, clopidogrel and nelfinavir (Cavallari 
et al., 2011; Dandara et al., 2011). The clopidogrel, an important antiplatelet agent, is a 
prodrug that requires hepatic bioactivation in order to produce its active metabolite. 
This bioactivation occurs in two oxidative steps, where several enzymes participate, 
including CYP2C19, which contributes for 45% of the first step and for 21% of the 
second (Figure 3) (Santos et al., 2011). Additionally, CYP2C19 enzyme has also a 
huge importance in the metabolism of proton pump inhibitors, such as omeprazole. 
This drug binds to the proton pump (H+/K+-ATPase) in gastric cells inhibiting the 
segregation of gastric acid, being a useful drug in the treatment of gastric acid-related 
disorders (Shirai et al., 2001; Yasui-Furukori et al., 2004; Uno et al., 2007). 
Omeprazole is metabolised in 2 different pathways, being extensively metabolised by 
CYP2C19 via (Palovaara et al., 2003; Furuta et al., 2005; Uno et al., 2007) (Figure 4). 
The CYP2C19 gene, located on chromosome 10q24.1-q24.3, is one of the most 
polymorphic enzymes of the CYP2C members, with many allelic variants described 
until today (http://www.cypalleles.ki.se/cyp2c19.htm) including CYP2C19*2 (rs4244285, 
c.681G>A, splicing defect), CYP2C19*3 (rs4986893, c.636G>A, p.W212X) and 
CYP2C19*17 (rs12248560, c.-806C>T, increased transcription). (Lee et al., 2009; 
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Tiwari et al., 2009; Daly, 2010). While CYP2C19*2 and CYP2C19*3 conduct to PM 
phenotypes, due to their genetic defect causing an inactive enzyme, CYP2C19*17 is 
related to UM phenotype because it is associated with increased levels of gene 
expression  (Brockmöller and Tzvetkov, 2008; Tiwari et al., 2009; Pilgrim et al., 2011). 
In case of treatments with clopidogrel, individuals that carry CYP2C19*2 have low 
concentration of the active metabolite, which leads to an ineffective inhibition of platelet 
function and consequently to increased risk of developing cardiovascular events, such 
as stent thrombosis and myocardial infarction. In contrast, individuals that carry 
CYP2C19*17 have a high concentration of the active metabolite due to increased 
enzymatic activity, which leads to an intensification of the inhibition of platelet function, 
what on one hand improves the response to antiplatelet treatment with clopidogrel, but 
on the other hand increases the risk of bleeding events (Santos et al., 2011; Voora and 
Ginsburg, 2012). 
Besides the differences observed in the bioactivation of clopidogrel, alterations in 
the metabolism of omeprazole and differences in the effectiveness of treatments have 
also been described. PM phenotype have increased duration of exposure of the proton 
pumps in parietal cells to high plasma concentration of omeprazole, leading to its 
inactivation by a longer period, and a better therapeutic efficiency. On the other hand, 
CYP2C19*17 is likely to promote increased metabolism of omeprazole that may cause 
a reduction in acid inhibition and consequently a therapeutic failure (Chaudhry et al., 
2008; Hunfeld et al., 2008; Gawrońska-Szklarz et al., 2010). 
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Figure 3. Clopidogrel metabolism. The clopidogrel is a prodrug that requires hepatic bioactivation for its active 
metabolite exert antiplatelet function. Adapted from Bonello et al. (2010) and Holmes et al. (2010). (Bonello et al., 
2010) (Holmes et al., 2010).  
 
 
 
Figure 4. Metabolic pathways of omeprazole by CYP isoenzymes. Omeprazole is mostly metabolised by CYP2C19 into 
5-hydroxyomeprazole, and then it is transformed into 5-hydroxyomeprazole sulfone by CYP3A4. A small portion of 
omeprazole is also metabolised by CYP3A4 into omeprazole sulfone, which is transformed into 5-hydromeprazole 
sulfone by CYP2C19. Adapted from Furuta et al. (2005). 
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2.2 Phase II of the drug metabolism 
 
In the phase II of drug metabolism, generally following the phase I, occurs the 
binding of an ionised group to the drug, forming a water-soluble product that facilitates 
their posteriorly extraction through the urine or bile (Liska, 1998; Guo et al., 2011). In 
this phase occur many conjugation reactions, specifically acetylation, glucuronidation, 
sulfation and methylation reactions (Pilgrim et al., 2011). In some situations, the phase 
II metabolite formed can be more pharmacologically active that their parent drug 
(Stachulski and Lennard, 2000). 
The enzymes with the most important role in this transformation are N-
acetyltransferase 1 and 2 (NAT1 and NAT2), glutathione transferase, thiopurine S-
methyltransferase (TPMT) and uridine diphosphate glucuronosyltransferase (Kudzi et 
al., 2011). 
 
 
2.2.1 Thiopurine S-methyltransferase – TPMT 
 
The thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme responsible for 
the S-methylation of thiopurine drugs, such as 6-mercaptopurine (6-MP), 6-thioguanine 
(6-TG) and azathioprine (AZA) (Kapoor et al., 2009; Pavlovic, 2009). These drugs are 
mostly used in the treatment of acute leukaemia and chronic inflammatory diseases 
(Román et al., 2012). When a thiopurine drug is absorbed by the organism, for 
example AZA, it is transformed in 6-MP in the liver and then is metabolised by 3 
different enzymatic pathways mediated by the Hypoxanthine phosphoribosyl-
transferase (HPRT), Xanthine oxidase (XO) and TPMT. While the HPRT pathway is the 
first step to the formation of the active metabolites that exert the cytotoxic effect (6-
TGNs), the other two pathways, TPMT and XO, inactivate the drug (Garat et al., 2008; 
Smith et al., 2009; Zabala-Fernández et al., 2011). The most important inactivation 
pathway of thiopurines in hematopoietic tissues is the TPMT pathway, since XO is 
nearly absent in this tissue. Moreover, TPMT activity has been described as inversely 
correlated to the accumulation of 6-TGNs and hematopoietic toxicity  (Krynetski and 
Evans, 2003) (Figure 5). 
The human TPMT gene, located in chromosome 6p22.3, exhibits a series of 
genetic polymorphisms that are responsible for the interindividual and interethnic 
variability of TPMT activity. Three main TPMT phenotypes can be distinguished: high 
methylator (HM), when the individuals inherit two functional alleles; intermediate 
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methylator (IM), when the individuals inherit one functional and one non-functional 
TPMT allele; and deficient methylator (DM), when the individuals inherit two non-
functional TPMT alleles (Spire-Vayron de la Moureyre et al., 1998; Pavlovic, 2009). In 
populations of European descent, about 90% of the individuals are HMs, expressing a 
normal enzymatic activity, approximately 10% are IMs, manifesting an intermediate 
activity and around 0.3% have DM phenotype, exhibiting a low or undetectable activity 
of TPMT enzyme (Garat et al., 2008; Zabala-Fernández et al., 2011). 
When patients with DM phenotype are treated with a standard dose of thiopurine 
drugs, they are at high risk of developing severe and even fatal hematopoietic toxicity, 
since the non-inactivation of the drug by TPMT, results in the  excessive accumulation 
of 6-TGNs in erythrocytes (Spire-Vayron de la Moureyre et al., 1998; Pavlovic, 2009). 
In these patients the dose of drug administrated must be reduced in order to prevent 
toxic effects. Patients with intermediate levels of TPMT activity would also benefit from 
a thiopurine dose adjustment, although the risk of toxic side effects is not so severe as 
for the DM individuals (Kapoor et al., 2009; Pavlovic, 2009).  
The TPMT*2 (rs1800462, c.238G>C, p.A80P), TPMT*3A (rs1800460, c.460G>A, 
p.A154T and rs1142345, c.719A>G, p.Y240C) TPMT*3B (rs1800460, c.460G>A, 
p.A154T) and TPMT*3C (rs1142345, c.719A>G, p.Y240C) are the most common  non-
functional alleles, usually accounting for 80 to 95% of IMs and DMs phenotypes in 
Eurasian populations (Garat et al., 2008; Pavlovic, 2009). Many other TPMT non-
functional alleles have been described, among which is TPMT*8 (rs56161402, 
c.644G>A, p.R215H), an allele mainly found in African populations (Oliveira et al., 
2007b; Roberts and Barclay, 2012). 
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Figure 5. Azathioprine metabolism. This drug is transformed in 6-MP and then is metabolised by the Hypoxanthine 
phosphoribosyl-transferase (HPRT), Xanthine oxidase (XO) and TPMT pathways. While HPRT pathway is the first step, 
forming 6-thioinosine monophosphate (6-TIMP) to form the cytotoxic elements 6-TGNs, the remaining two pathways are 
the initial steps to eliminate thiopurines from the body, forming 6-thiouric acid (6-TU), 6-methylmercaptopurine (6-MMP) 
and 6-methylthioinosine monophosphate (6-MTIMP). Adapted from Smith et al. (2009) and Zabala-Fernández et al. 
(2011). 
 
 
2.2.2 N-acetyltransferase 2 – NAT2 
 
The N-acetyltransferase 2 (NAT2) enzyme intervenes in phase II of drug 
metabolism and is responsible for the acetylation of various drugs such as isoniazid 
and sulfamethoxazole as well as several nefarious components like heterocyclic and 
aromatic amines  (Fuselli et al., 2007). The metabolism of isoniazid (INH), an important 
anti-tuberculosis drug, is one of the most well studied Pharmacogenetic examples. Its 
metabolism occurs in the liver, where it is biotransformed to acetylisoniazid by NAT2, 
hydrolysed to acetylhydrazine and posteriorly oxidised by CYP2E1, forming 
hepatotoxic metabolites. In another metabolic pathway of INH, NAT2 is also 
responsible for the transformation of hydrazine, the major hepatotoxic metabolite of 
INH, into acetylhydrazine that subsequently is oxidised by CYP2E1. Furthermore, 
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NAT2 also participates in the biotransformation of acetylhydrazine into a harmless 
component, diacetylhydrazine (Teixeira et al., 2011; Lv et al., 2012) (Figure 6).  
The NAT2 gene, located in human chromosome 8p22, is polymorphic with over 30 
SNPs described in its coding region, including some rare mutations observed in 
different human populations. Among these, the most common SNPs are c.191G>A 
(rs1801279, p.R64Q), c.282C>T (rs1041983, p.Y94Y) c.341T>C (rs1801280,p.I114T), 
c.481C>T (rs1799929, p.L161L), c.590G>A (rs1799930, p.R197Q), c.803A>G (rs1208, 
p.K268R), c.857G>A (rs1799931, p.G286E),  identified in different populations  (Fuselli 
et al., 2007; Rios-Santos and Magno, 2012; Teixeira et al., 2013). 
The combination of NAT2 polymorphisms is commonly used to infer the NAT2 
acetylation status, which are designated as haplotypes (Rios-Santos and Magno, 
2012). Three different acetylator phenotypes have been described: rapid (RA), 
intermediate (IA) and slow acetylator (SA) phenotypes, if the individual inherits 2, 1 or 0 
full functioning haplotypes, respectively (Hiratsuka et al., 2006; Fuselli et al., 2007). 
Although it is assumed that the phenotype prediction of NAT2 activity through 
genotyping methods is very useful, so far there is still no agreement about the 
minimum number of NAT2 SNPs necessary to infer with accuracy the human acetylator 
status. The 7-SNP based genotypic approach is the most conventional method used 
due to its good sensitivity and specificity (Selinski et al., 2011; Rios-Santos and Magno, 
2012). However, in a recent study of Selinski et al. (2011) the NAT2 phenotypes were 
determined and the sensibility and specificity of the conventional 7-SNP genotype was 
compared to that of a recently published tagSNP (rs1495741). When the authors 
further evaluated whether a novel SNP panel could outperform the two others, they 
found out that both the tagSNP and the 7-SNP inferred genotypes had a high 
sensibility to predict slow acetylators, although the tagSNP showed an inferior 
specificity due to misclassifying some rapid and slow acetylators. Interestingly, a 
combination of only two SNPs (c.282C>T, rs1041983 and c.341T>C, rs1801280) that 
had the same sensitivity and specificity as the 7-SNP genotype was also identified. 
These results, which have been corroborated in the study of Hein et al. (2012), may 
have a practical importance, because of the capability to obtain the same information 
with less SNPs genotyping, thus saving costs and time (Selinski et al., 2011; Hein and 
Doll, 2012). 
In recent studies, the SA phenotype has been associated with a higher risk of 
developing drug-induced hepatotoxicity than RA or even IA in tuberculosis treatments 
with INH (Teixeira et al., 2011; Wang et al., 2012; Teixeira et al., 2013). Additionally, 
the low acetylation also affects the metabolism of acetylhydrazine into non-toxic 
metabolite, diacetylhydrazine, increasing the rate of accumulation of INH toxic 
FCUP 32 
A study on Pharmacogenetic polymorphisms in the Portuguese Gypsies 
   
metabolites. It has been also shown that in SAs the serum concentration of hydrazine 
was significantly higher than in RAs, possibly due to increased INH concentration 
(Teixeira et al., 2013). 
 
 
 
 
Figure 6. Isoniazid metabolism. This drug is biotransformed into acetylisoniazid by NAT2, hydrolysed into 
acetylhydrazine and posteriorly oxidised by CYP2E1, forming toxic metabolites. These metabolites are conjugated with 
glutathione S-transferase (GST) and then excreted. In another metabolic pathway of isoniazid, hydrazine is 
biotransformed by NAT2 into acetylhydrazine that subsequently is oxidised by CYP2E1. Furthermore, NAT2 also 
participates in the biotransformation of acetylhydrazine into diacetylhydrazine, a harmless component. Adapted from 
Teixeira et al. (2011), Rios-Santos and Magno (2012) and Teixeira et al. (2013).  
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3. Drug targets 
 
Despite the absence of a tight definition for what drug targets are, according to 
Imming et al. (2006) they are molecular structures that pass through a specific 
interaction with a drug (target-drug interactions) administered to treat a disease 
(Imming et al., 2006).  
Several medicines need to interact with particular targets to exert their 
pharmacologic effect. When polymorphisms occur in genes that codify these targets, 
the sensibility to selected drugs may be influenced and consequently it may affect the 
response of the patient to the treatment. These polymorphisms can have a significant 
relevance in cases where interindividual variations in drug plasma concentrations are 
minimal, but major pharmacodynamic differences can be detected (Kupiec et al., 2006; 
Musshoff et al., 2010; Kudzi et al., 2011). 
An example of a drug target polymorphism is the warfarin, which acts by the 
inhibition of the VKORC1 (Kupiec et al., 2006; Yoshizawa et al., 2009).  
 
  
3.1 Vitamin K epoxide reductase complex subunit 1 – VKORC1 
 
The complex 1 of vitamin k epoxide reductase (VKORC1), is essential in the 
vitamin k recycling cycle (Markatos et al., 2008; Kwon et al., 2011). The enzyme is 
responsible for the transformation of vitamin k in its reduced (active) form which is 
indispensable for the post-translational gamma-carboxylation of vitamin K-dependent 
clotting factors (Miao et al., 2007). 
VKORC1 is the target of several coumarin-based anticoagulant drugs, being 
warfarin the most frequently prescribed for prevention of thrombotic diseases (Miao et 
al., 2007; Wang et al., 2008). This anticoagulant drug exerts its pharmacologic effect by 
inhibiting the enzyme VKORC1, therefore affecting the synthesis of vitamin K- 
dependent clotting factors (Limdi and Veenstra, 2008; Kwon et al., 2011) (Figure 7). 
In the encoding gene, VKORC1, located on chromosome 16p12-21q, several 
genetic variants that alter the sensibility to warfarin have been reported (Montes et al., 
2006; Yoshizawa et al., 2009; Scibona et al., 2012). 
The c.-1639G>A (rs9923231) polymorphism, the most common variant in 
Caucasian populations, has been the most widely studied for warfarin and 
acenocoumarol drugs (Wu, 2007; Markatos et al., 2008). 
FCUP 34 
A study on Pharmacogenetic polymorphisms in the Portuguese Gypsies 
   
This polymorphism is associated with a reduction of mRNA expression, with 
consequent  reduction of the VKORC1 activity and warfarin dose requirements (Kwon 
et al., 2011).  Thus, patients with c.-1639AA genotype, require a lower dose of warfarin 
than those with c.-1639GG genotype (Wu, 2007; Kwon et al., 2011; Smires et al., 
2012). 
 
 
 
Figure 7. Warfarin effects as vitamin K anticoagulant. This drug interferes with the cyclic inter-conversation of vitamin K, 
reducing the coagulant activity. Adapted from D’Andrea et al. (2008) and Limdi and Veenstra, (2008).  
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4. Worldwide population distribution of pharmacogenetically 
relevant polymorphisms        
 
If Pharmacogenetics deals with drug metabolism phenotypes which are partly 
determined by inherited variations in genes encoding for enzymes, transporters and 
targets involved in the process of drug metabolism, there is no doubt that a main 
founder pillar of the discipline is human genetic diversity. Along the past decades many 
studies have revealed that the frequency of alleles influencing drug response exhibit a 
great variation among different population groups and even within the same population 
group (Kupiec et al., 2006; Musshoff et al., 2010; Kudzi et al., 2011). For example, the 
frequency of the CYP2C19 PMs is lower in Western Caucasians than that observed 
among Orientals (Musshoff et al., 2010). On the other hand, CYP2C9*2 allele is rarely 
detected in Asian populations, while CYP2C9*3 is reported with a frequency at 1.1-
6.8% in this population (Kudzi et al., 2011).  
Acknowledging this information, Pharmacogenetics has grown hand in hand with 
extensive population studies aimed at characterising adequately each different 
population. European populations have been the centre of many of these 
investigations, leading to obtain a reasonable picture on patterns of pharmacogenetic 
diversity in Europe. Still, in this regard there are some populations that were poorly 
studied until now, such as the Gypsy groups.  
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5. Portuguese Gypsies 
 
In the second half of 15th century, coming from the trans-Pyrenees route arrived at 
Iberia the founding populations that today are known as Gypsies in Portugal. The 
almost absence of historical records about the ancient people migrations from which 
would arose the Gypsies, does not allow specifying the origin of these populations, 
however, evidence coming first from linguistics and more recently from genetic studies 
both point to India as the region from where departed the proto-Roma populations 
(Gusmão et al., 2008; Mendizabal et al., 2011). 
As Gusmão et al. (2008) highlight in their research, while Roma as a whole behave 
as a transnational genetic isolate, each Roma population presents its specificities, as 
was observed in Portuguese Gypsies. Roma groups normally have a small population 
size, with a strong social and cultural identity, where endogamous practices 
predominate (Gresham et al., 2001). From a genetic viewpoint this leads to the 
occurrence of high drift effects, what induced the differentiation between the gypsy 
groups and the host populations, reduced genetic diversity, high linkage disequilibrium 
and a limited gene flow between Gypsy groups (Gusmão et al., 2008; Valente et al., 
2009). Accordingly, no Gypsy group can be genetically representative of others. For 
these reasons, the Roma have attracted attention from diverse areas of study like, 
among others, Epidemiology, which would lead to identify a number of Mendelian 
disorders caused by private founder mutations, and Population Genetics, which is 
giving important contributions to the reconstruction of the Roma history (Kalaydjieva et 
al., 2001; Gusmão et al., 2010; Fehér et al., 2011). 
In the field of Pharmacogenetics, very few studies were performed up to date 
focusing on Roma populations, which justifies having elected in this study the 
Portuguese Gypsies to be analysed from the pharmacogenetic point of view, 
attempting to understand how much they differ from the host population in which regard 
genetic polymorphisms influence drug response. 
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II. AIMS 
 
 
Although the Portuguese Gypsies have been demonstrated to be quite 
differentiated from the Portuguese host population, they remain virtually unstudied in 
the context of Pharmacogenetics and Forensic Toxicology. Thus, the aim of this study 
was to characterise the Portuguese Gypsies for single nucleotide polymorphisms 
(SNP) known to have pharmacogenetic implications, in order to evaluate whether they 
show any peculiarity in which respect the assessed fraction of diversity that influences 
drug response. 
To achieve this main goal, the following specific aims were established: 
1. Selection of SNPs with pharmacogenetic relevance and development of 
PCR and minisequencing multiplex reactions; 
2. Characterisation of a sample of Portuguese Gypsies and another of 
Portuguese non-Gypsies for the selected SNPs; 
3. Comparison of the results obtained in the two population samples; 
4. Analysis in a worldwide context of the results obtained in this study. 
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III. MATERIAL AND METHODS 
 
 
1. Samples and DNA extraction 
 
For the purpose of the present study, a sample consisting of 116 individuals who 
self-identified as Portuguese Gypsies was analysed. To perform comparative analyses, 
a control group of 70 Portuguese non-Gypsy individuals was also studied.  
All samples have been extracted for previous works by the Chelex®-100TM (BioRad) 
method described by Lareu et al. (1994).      (Lareu et al., 1994) 
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2. Multiplex PCR Design 
 
 
2.1 Selection of Target Polymorphisms 
 
In the beginning of this project, a careful bibliographic analysis was conducted to 
select genes with pharmacogenetic relevance and potential forensic applications. A 
total of 5 genes have been selected: CYP2C9 and CYP2C19 that encode important 
enzymes of the phase I of the drug metabolism; TPMT and NAT2, which codify 
relevant enzymes for phase II, and VKORC1 that codify a drug target. For the selection 
of the variations to be studied, the impact caused to protein activity and reported allelic 
frequencies in Caucasian populations have been taken into consideration. 
From the CYP2C9 gene were selected CYP2C9*2 and CYP2C9*3 allelic variants, 
that represent about 85% of PM phenotypes and from CYP2C19 was chosen 
CYP2C19*2, which is relatively common in Caucasian populations and accounts for 
75-83% of PM phenotypes (Bozina et al., 2003; Bravo-Villalta et al., 2005). On the 
other hand, 4 SNPs from the TPMT gene were selected, TPMT*2, TPMT*3B, 
TPMT*3C and TPMT*8, being the first 3 responsible for 80-95% of IM and DM 
phenotypes and 2 SNPs of the NAT2 gene, c.282C>T and c.341T>C, which were 
chosen based on their accuracy to predict the NAT2 acetylator phenotypes (Garat et 
al., 2008; Selinski et al., 2011). At last, VKORC1 c.-1639G>A was selected due to its 
significance in drug-target interaction (Smires et al., 2012). 
 
 
2.2 Multiplex PCR amplification 
 
The multiplex PCR has been developed to amplify, at the same time, the various 
fragments containing the target SNPs. 
In a previous study, a multiplex PCR for TPMT gene was designed, being in the 
present work enriched the with new amplification primers for the remaining genes of 
interest. 
 The gene sequences were obtained from Ensemble Genome Browser (Ensembl 
release 68 – July 2012) (http://www.ensembl.org/index.html) and Primer 3 v.0.4.0 
Software (http://frodo.wi.mit.edu/) was used to design the amplification primers (Rozen 
and Skaletsky, 2000), preventing annealing in polymorphic regions. Furthermore, these 
primers were also designed according to the melting temperature (Tm) of the previous 
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multiplex PCR, 59ºC, to ensure the action of all primers at the same conditions. Each 
of the primers obtained by Primer 3 was tested in BLAT (UCSC) 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start), selecting only the human 
genome, in order to detect possible non-specific annealing, which could reduce the 
efficiency of the reaction. Then each pair of primers was also tested in UCSC In-Silico 
PCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start) to detect possible non-
specific amplifications. 
The last step of multiplex development consisted in testing with AutoDimer 
Software v1.0 and Oligocalc 
(http://www.basic.northwestern.edu/biotools/OligoCalc.html) if the designed 
amplification primers could form primer-dimer structures and/or hairpins, which could 
contribute to reduce the reaction efficiency (Vallone and Butler, 2004). Detailed 
information about amplification primers, amplified products and the selected SNPs is 
present in Table 1. 
 
 
 Table 1. Amplification primers and their characteristics. 
 
 
 
After the in silico evaluation, each primers pair was tested in individual amplification 
reactions, to confirm if they operate correctly. 
Before the multiplex amplification reaction, a mix including all forward and reverse 
primers was prepared, in which each primer was in a final concentration of 2 μM. The 
multiplex PCR reactions were performed in a final volume of 10 μL, containing 5 μL of 
Gene SNP Allele Forward primer 5’-3’ (bp) Reverse primer 5’-3’ (bp) 
Product 
Size 
TPMT rs1800462 c.238G>C TCTTTGAAACCCTATGAACCTGA TGCGTGCTAAATAGGAACCAT 377 
TPMT rs1800460 c.460G>A TGTTGAAGTACCAGCATGCAC AGCCTTACACCCAGGTCTCT 365 
TPMT rs1142345 c.719A>G 
GAATCCCTGATGTCATTCTTCA CCTCAAAAACATGTCAGTGTGA 213 
TPMT rs56161402 c.644G>A 
CYP2C9 rs1799853 c.430C>T GGAGGATGGAAAACAGAGACTTACA AAGGTCAGTGATATGGAGTAGGG 309 
CYP2C9 rs1057910 c.1075A>C TACCCCTGAATTGCTACAACAAA GAATTTAATGTCACAGGTCACTGC 238 
CYP2C19 rs4244285 c.681G>A CAACCAGAGCTTGGCATATTG TAAAGTCCCGAGGGTTGTTGAT 223 
NAT2 rs1041983 c.282C>T 
AGAGGCTATTTTTGATCACATTG GTGTTTCTTCTTTGGCAGGAGAT 403 
NAT2 rs1801280 c.341T>C 
VKORC1 rs9923231 c.-1639G>A GGAGAGGGAAATATCACAGACG CTCCTGACCTCAAGTGATCCA 189 
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MyTaqTM HS Mix (Bioline), 1 μL of Primer Mix, 1 μL of DNA and 3 μL of deionized 
water. The amplification was performed at 95ºC for 15 min, followed by 5 cycles at 
94ºC for 30 sec, 63ºC for 90 sec, 72ºC for 1 min, and another 30 cycles at 94ºC for 30 
sec, 59ºC for 90 sec, 72ºC for 1 min and a final extension at 72ºC for 10 min. 
The amplification reactions were done in 2720 Thermal Cycler (Applied 
Biosystems) or/and Thermal Cycler (BioRad).  
 
 
2.3 Electrophoresis 
 
Polyacrylamide gel (T9C5) electrophoresis was performed for all samples in order 
to test the success of the amplification reactions and also identify possible 
contaminations. The polyacrylamide gel was stained following the Silver staining 
procedure (Qu et al., 2005). 
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3. SNP genotyping 
 
The genotypic data from the 10 SNPs in study was obtained through the SNaPshot 
or minisequencing technique described below. 
 
 
3.1 Multiplex Single Base Extension  
 
To perform the minisequencing reactions, 10 single base extension (SBE) primers 
were designed following the same steps used for amplification primers, but ending 
immediately adjacent to the target SNPs. 
For each SNP, 2 possible extension primers could be designed, forward and 
reverse, but only one was selected based on the best conditions for the 
minisequencing reaction according to the Software Primer3. The SBE primers of 
CYP2C9 SNPs have a degenerated position (indicated in red at the table) because 
they anneal with polymorphic sites that could lead to preferential amplification of one of 
the alleles.   
To produce differences in electrophoretic mobility, a non-annealing tail with different 
sizes was added to the SBE primers. The SBE primers and their characteristics are 
present in Table 2. 
 
Table 2. Single Base Extension Primers and their characteristics. 
 
 
Gene SNP Allele SBE primer sequences 5’-3’ Length 
Final  
length 
Detection 
TPMT rs1800462 c.238G>C AATGTATGATTTTATGCAGGTTT 23 23 G/C 
TPMT rs1800460 c.460G>A TGACATGATTTGGGATAGAGGA 22 31 G/A 
TPMT rs1142345 c.719A>G TGTCTCATTTACTTTTCTGTAAGTAGA 27 36 T/C 
TPMT rs56161402 c.644G>A TTTCAGGTAAAATATGCAATATAC 24 48 G/A 
CYP2C9 rs1799853 c.430C>T GGAAGAGGAGCATTGAGGAY 20 53 C/T 
CYP2C9 rs1057910 c.1075A>C GTGCACGAGGTCCAGAGRTAC 21 58 A/C 
CYP2C19 rs4244285 c.681G>A GTTTTTAAGTAATTTGTTATGGGTTCC 27 68 C/T 
NAT2 rs1041983 c.282C>T GTGCTGTATTTGTTAACTGGAGGGAT 26 63 G/A 
NAT2 rs1801280 c.341T>C CCTTCTCCTGCAGGTGACCA 20 42 T/C 
VKORC1 rs9923231 c.-1639G>A GAAAAACAACCATTGGCC 18 18 G/A 
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3.2 Minisequencing protocol 
 
Before the minisequencing reactions, an initial purification with ExoSAP-IT® was 
performed in order to remove the excess of dNTPs and primers present in the PCR 
product. Each purification reaction contained 1 µL of amplified product and 0.8 µL of 
ExoSAP-IT® (USB® Products) and the protocol used was 37ºC for 15 min and 85ºC for 
another 15 min.  
A mix including all SBE primers was prepared, containing 0.4 µL of the VKORC1 
SBE primer and 0.2 µL of the remaining SBE primers, all with an initial concentration of 
20 µM.   
The SNaPshotTM reactions were performed in a final volume of 5 µL using 1.8 µL of 
purified PCR product, 2.2 µL of SBE primers mix and 1 µL of SNaPshotTM Multiplex Kit 
(Applied Biosystems). The reaction conditions were 25 cycles at 96ºC for 10 sec, 50ºC 
for 5 sec and 60ºC for 30 sec. 
The final products of the SNaPshot reactions were treated with 1 µL of SAP 
enzyme (USB®) at 37ºC for 60 min and 85ºC for 15 min, to eliminate unincorporated 
ddNTPs.  
These reactions were carried out in a 2720 Thermal Cycler (Applied Biosystems) 
or/and Thermal Cycler (BioRad). 
Finally, 3 µL of the minisequencing-purified products were mixed with 12 µL of Hi-
DiTM Formamide (Applied Biosystems) and GeneScanTM-120 LIZTM size standard. 
Capillary electrophoresis was then performed in an ABI 3130 Genetic Analyser 
(Applied Biosystems).  
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4. Sanger Sequencing 
 
The Sanger sequencing technique was performed to validate the results obtained in 
multiplex PCR and SNaPshot reactions. 
An initial purification with ExoSAP-IT® was performed, such as in minisequencing 
procedure, to eliminate the elements that were not consumed in the amplification 
reaction. Each purification reaction contained 1.5 µL of amplified product and 0.5 µL of 
ExoSAP-IT®. The reaction conditions were described in section 3.2. 
The sequencing reactions were prepared in a total volume of 5 μL, containing 2 μL 
of purified PCR product, 1 μL of the amplification primer (forward or reverse) at 2 μM, 1 
μL of BigDye sequencing kit and 1 μL of sequencing buffer. The protocol used was 
96ºC for 4 min, followed by 35 cycles at 96ºC for 10 sec, 55ºC for 5 sec and 60ºC for 4 
min,  and a final step at 60ºC for 10 min. 
The reactions were executed in 2720 Thermal Cycler (Applied Biosystems) or/and 
Thermal Cycler (BioRad). 
Then, the sequencing products were purified in Sephadex® columns (750 μL) 
through centrifugation for 4 minutes at 4400 rpm.  
The final products were resuspended in 12 μL of Hi-DiTM Formamide and capillary 
electrophoresis was performed in an ABI 3130 Genetic Analyser (Applied Biosystems).  
     
FCUP 45 
A study on Pharmacogenetic polymorphisms in the Portuguese Gypsies 
   
5. Data analysis 
 
The results of SNaPshot were analysed with GeneMapper® v4.0 and Peak 
ScannerTM v1.0 Softwares and the sequencing data was analysed with Sequencing 
Analysis v5.2 and Geneious Pro 5.5.8. 
The Arlequin Software v3.5 was used to determine the allelic frequencies, to test 
departures from Hardy-Weinberg Equilibrium and to perform the Fisher’s exact test 
(Excoffier and Lischer, 2010). The significant level assumed for these tests was 
adjusted applying the Bonferroni correction. 
The STATISTICA 10 software was also used to execute the Principal Components 
& Classification Analysis (Version 10, 2010). 
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IV. RESULTS AND DISCUSSION 
 
 
1. Locus by locus approach 
 
The PCR and minisequencing multiplex reactions were developed with success. In 
figure 8 is observed an example of the pattern bands of the PCR multiplex reaction in 
polyacrylamide gel and in figure 9 is observed an example of an electropherogram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Polyacrylamide gel. Band patterns observed after the electrophoresis and respective fragments length and 
SNPs. 
 
 
 
 
 
Figure 9. Electropherogram obtained after multiplex minisequencing analysis. For the polymorphisms c.719A>G, 
c.282C>T and c.681G>A were designed reverse extension primers, leading to the detection of the complementary base.  
c.-1639G>A  c.238G>C c.460G>A c.719A>G c.341T>C c.644G>A c.430C>T c.1075A>C c.282C>T c.681G>A 
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The genotypic distributions observed for each of the scrutinized variations were 
tested for Hardy-Weinberg Equilibrium with the Arlequin software. No significant 
deviations were found in the Gypsies or in the non-Gypsies samples (Supplementary 
Table 1). 
 
 
1.1 Cytochrome P450 2C9 - CYP2C9 
 
As previously referred, the CYP2C9 is an important metabolic enzyme responsible 
for the metabolism of diverse drugs, some of them with a narrow therapeutic index, 
such as Warfarin (Xie et al., 2002).  
The two selected SNPs, CYP2C9*2 and CYP2C9*3, are responsible for a reduction 
of the enzymatic capacity of CYP2C9 and the individuals that carry one or both of 
these variants can more frequently develop ADRs than the individuals that carry only 
wild-type alleles (CYP2C9*1) (Carlquist et al., 2006; Yousef et al., 2012).  
In this study, the allelic frequencies of CYP2C9*2 and CYP2C9*3 in the Portuguese 
non-Gypsy and Gypsy populations were estimated and are presented in Table 3. 
 
 
Table 3. Allele frequencies of CYP2C9 in the Portuguese non-Gypsy and Gypsy populations. 
 
 
 
 
 
 
 
 
 
To assess whether differences between frequencies of CYP2C9*2 and CYP2C9*3 
in the two populations were statistically significant, Fisher exact tests of population 
differentiation were performed, revealing a significant difference for CYP2C9*2 
(p=0.02070±0.0018), whereas, no significant difference was found for CYP2C9*3 (p= 
0.53454±0.0027). 
Next, comparisons were extended to diverse worldwide populations, for which data 
had been previously published and collected from the bibliography. Among them was 
included another sample from Portugal that had been previously characterised by 
CYP2C9 
Portuguese non-Gypsies 
(n)  
Portuguese Gypsies 
(n)   
CYP2C9*2 0.200±0.035 (70) 0.108±0.020* (116) 
CYP2C9*3 0.057±0.020 (70) 0.079±0.018 (114) 
*Significant value (p ≤0.05) 
n, sample size 
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Oliveira et al. (2007a). The Fisher exact test was also applied in these comparisons to 
evaluate if the differences observed between allelic frequencies had statistical 
significance, using the significance level of inferred after the application of the 
Bonferroni correction for multiple tests. The p-values obtained in the comparisons are 
present in Table 4 for CYP2C9*2 and in Table 5 for CYP2C9*3. 
In general, the allele frequency of CYP2C9*2 in the Portuguese non-Gypsies had 
significant differences comparatively to values found in most of the African and Asian 
populations. In contrast, when it was compared with frequencies reported for European 
populations the majority of the differences had no statistical significance, as well as did 
not differences with the available population samples from America, among which were 
not included representatives of Native-Americans. 
Similar results were observed when the allele frequency of CYP2C9*2 in the 
Portuguese Gypsies was compared with worldwide data.  
For CYP2C9*3, the Portuguese non-Gypsy sample only showed significant 
differences with Benin, Ghana and the Roma from Hungary, whereas the Portuguese 
Gypsies significantly differed from Benin, Ghana, USA African-Americans and Japan.  
As shown in Table 4 and 5, Spikey et al. (2009b) had provided data for the Roma 
from Hungary regarding to the two CYP2C9 alleles here examined. Interestingly, when 
compared to the Portuguese Gypsies, the Hungarian Roma did not showed differences 
at CYP2C9*2 and CYP2C9*3, whereas comparatively to the Portuguese non-Gypsies 
they differed significantly at CYP2C9*3 allele. 
A special attention was also given to the comparisons between the Portuguese 
Gypsies and Indian populations, since linguistic and genetic evidence indicate that the 
Northern region of the Indian sub-continent, was likely the original homeland of the 
migrants from whom the current Roma arose (Pereira et al., 2012). In the studies of 
Nahar et al. (2013) and Jose et al. (2005) were also estimated CYP2C9*2 and 
CYP2C9*3 frequencies in North and South India, respectively. When the allelic 
frequencies of the Portuguese Gypsies were compared with values for North India, 
differences were not found to be statistically significant for any of the two alleles. 
However, the frequency of CYP2C9*2 in the Portuguese Gypsies significantly differed 
from that reported for South India. 
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Table 4. Comparison of allele frequencies of CYP2C9*2 reported from different ethnic populations. 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 Benin 111 0 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Allabi et al., 
2003) 
 Egypt 247 0.120 0.01564±0.0017* 0.71072±0.0048 
(Hamdy et 
al., 2002) 
 Ethiopia 150 0.043 0.00000±0.0000
*†
 0.00706±0.0007
*
 
(Scordo et 
al., 2001) 
 Ghana 204 0 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Kudzi et al., 
2009) 
 South Africa 993 0
 
0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Dandara et 
al., 2011) 
America       
 African-American 100 0.010 0.00000±0.0000
*†
 0.00003±0.0000
*†
 
(Hamdy et 
al., 2002) 
 Argentina 101 0.262 0.19927±0.0088 0.00002±0.0000
*†
 
(Scibona et 
al., 2012) 
 Ashkenazi Jewish 510 0.127 0.02591±0.0014* 0.43004±0.0096 
(Scott et al., 
2008) 
 Bolivia 778 0.048 0.00000±0.0000
*†
 0.00032±0.0001
*†
 
(Bravo-
Villalta et al., 
2005) 
 Sephardi Jewish 80 0.194 1.00000±0.0000 0.01714±0.0017* 
(Scott et al., 
2008) 
 USA 140 0.132 0.08654±0.0050 0.41993±0.0088 
(Dickmann 
et al., 2001) 
Asia       
 China 394 0.001 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Yang et al., 
2003) 
 Iran 150 0.253 0.23076±0.0025 0.00001±0.0000
*†
 
(Azarpira et 
al., 2010) 
 Japan 341 0 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Yoshizawa 
et al., 2009) 
 Jordania 263 0.135 0.05817±0.0028 0.34428±0.0072 
(Yousef et 
al., 2012) 
 Korea 358 0 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Bae et al., 
2005) 
 Lebanon 146 0.113 0.01564±0.0017* 0.89184±0.0021 
(Saad and 
Langaee, 
2011) 
 Malaysia 85 0.006 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Gan et al., 
2011) 
 North India 209 0.050 0.00000±0.0000
*† 
0.00924±0.0012* 
(Nahar et 
al., 2013) 
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Continuation of the previous table. 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
       
 Saudi Arabia 131 0.133 0.08004±0.0026 0.41258±0.0081 
(Alzahrani 
et al., 
2013) 
 South India 346 0.040 0.00000±0.0000
*†
 0.00038±0.0002
*†
 
(Jose et 
al., 2005) 
 Turkey 85 0.100 0.01589±0.0014* 0.87448±0.0017 
(Babaoglu 
et al., 
2004) 
Europe       
 Belgium 121 0.100 0.00815±0.0009* 0.76622±0.0048 
(Allabi et 
al., 2003) 
 Croatia 200 0.165 0.34634±0.0068 0.05097±0.0034 
(Bozina et 
al., 2003) 
 Denmark 276 0.121 0.01623±0.0016* 0.62487±0.0068 
(Pedersen 
et al., 
2010) 
 Faroe Islands 311 0.088 0.00044±0.0002
*†
 0.43034±0.0099 
(Pedersen 
et al., 
2010) 
 France 151 0.150 0.21672±0.0088 0.20514±0.0078 
(Yang et 
al., 2003) 
 Germany 118 0.140 0.14210±0.0045 0.33511±0.0041 
(Burian et 
al., 2002) 
 Greece 283 0.129 0.04065±0.0039
*
 0.47106±0.0053 
(Arvanitidi
s et al., 
2007) 
 Hungary 535 0.125 0.01698±0.0021* 0.50442±0.0079 
(Sipeky et 
al., 2009b) 
 Hungary (Gypsy) 465 0.118 0.01021±0.0016* 0.72840±0.0037 
(Sipeky et 
al., 2009b) 
 Italy 360 0.125 0.02355±0.0032* 0.55310±0.0081 
(Scordo et 
al., 2004) 
 Norway 328 0.099 0.00125±0.0004
*
 0.71109±0.0070 
(Pedersen 
et al., 
2010) 
 Portugal 125 0.132 0.08395±0.0052 0.47511±0.0039 
(Oliveira et 
al., 2007a) 
 Romania 332 0.113 0.00935±0.0016* 0.90333±0.0024 
(Buzoianu 
et al., 
2012) 
 Russia 290 0.105 0.00317±0.0007* 0.90394±0.0015 
(Gaikovitc
h et al., 
2003) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.001 
n, sample size 
q, frequencies of the minor allele  
Ref., references 
Continuation of the previous table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
 Slovenia 127 0.122 0.05245±0.0017 0.67028±0.0057 
(Herman 
et al., 
2003) 
 Spain 200 0.120 0.02276±0.0027* 0.69737±0.0053 
(Mas et 
al., 2005) 
 Sweden 1490 0.113 0.00508±0.0010* 0.91801±0.0018 
(Wadelius 
et al., 
2009) 
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Table 5. Comparison of allele frequencies of CYP2C9*3 reported from different ethnic populations. 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 Benin 111 0 0.00061±0.0002*
†
 0.00000±0.0000*
†
 
(Allabi et 
al., 2003) 
 Egypt 247 0.060 1.00000±0.0000 0.40683±0.0071 
(Hamdy et 
al., 2002) 
 Ethiopia 150 0.023 0.09045±0.0024 0.00312±0.0007* 
(Scordo et 
al., 2001) 
 Ghana 204 0 0.00000±0.0000*
†
 0.00000±0.0000*
†
 
(Kudzi et 
al., 2009) 
America       
 African-American 100 0.005 0.00375±0.0005* 0.00009±0.0000*
†
 
(Hamdy et 
al., 2002) 
 Argentina 101 0.030 0.26901±0.0039 0.03329±0.0016* 
(Scibona 
et al., 
2012) 
 Ashkenazi Jewish 510 0.081 0.40291±0.0064 1.00000±0.0000 
(Scott et 
al., 2008) 
 Bolivia 778 0.030 0.12696±0.0020 0.00114±0.0005* 
(Bravo-
Villalta et 
al., 2005) 
 Sephardi Jewish 80 0.144 0.02086±0.0019* 0.04227±0.0034* 
(Scott et 
al., 2008) 
 USA 140 0.043 0.62699±0.0046 0.09765±0.0046 
(Dickmann 
et al., 
2001) 
Asia       
 China 394 0.036 0.23142±0.0033 0.00927±0.0006* 
(Yang et 
al., 2003) 
 Iran 150 0.098 0.19955±0.0053 0.53338±0.0048 
(Azarpira 
et al., 
2010) 
 Japan 341 0.021 0.03750±0.0014* 0.00022±0.0001*
†
 
(Yoshizaw
a et al., 
2009) 
 Jordania 263 0.068 0.71311±0.0032 0.64234±0.0040 
(Yousef et 
al., 2012) 
 Korea 358 0.060 1.00000±0.0000 0.35730±0.0080 
(Bae et al., 
2005) 
 Lebanon 146 0.096 0.18839±0.0065 0.53423±0.0079 
(Saad and 
Langaee, 
2011) 
 Malaysia 85 0.041 0.60368±0.0026 0.14645±0.0026 
(Gan et 
al., 2011) 
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Continuation of the previous table. 
 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
 North India 209 0.110 0.06837±0.0043 0.21124±0.0065 
(Nahar et 
al., 2013) 
 Saudi Arabia 131 0.023 0.08866±0.0020 0.00572±0.0011* 
(Alzahrani 
et al., 
2013) 
 South India 346 0.080 0.48582±0.0027 1.00000±0.0000 
(Jose et 
al., 2005) 
 Turkey 85 0.088 0.38896±0.0052 0.85456±0.0026 
(Babaoglu 
et al., 
2004) 
Europe       
 Belgium 121 0.074 0.67586±0.0030 0.86319±0.0020 
(Allabi et 
al., 2003) 
 Croatia 200 0.095 0.21493±0.0042 0.56737±0.0041 
(Bozina et 
al., 2003) 
 Denmark 276 0.053 0.83493±0.0020 0.17889±0.0047 
(Pedersen 
et al., 
2010) 
 Faroe Islands 311 0.053 0.83322±0.0019 0.18491±0.0034 
(Pedersen 
et al., 
2010) 
 France 151 0.080 0.43940±0.0065 1.00000±0.0000 
(Yang et 
al., 2003) 
 Germany 118 0.050 0.81451±0.0010 0.25619±0.0056 
(Burian et 
al., 2002) 
 Greece 283 0,081 0.37836±0.0071 1.00000±0.0000 
(Arvanitidi
s et al., 
2007) 
 Hungary 535 0.088 0.25441±0.0062 0.79412±0.0035 
(Sipeky et 
al., 2009b) 
 Hungary (Gypsy) 465 0.155 0.00085±0.0002*
†
 0.00158±0.0004* 
(Sipeky et 
al., 2009b) 
 Italy 360 0.097 0.14524±0.0041 0.50615±0.0057 
(Scordo et 
al., 2004) 
 Norway 328 0.065 0.84796±0.0017 0.53567±0.0056 
(Pedersen 
et al., 
2010) 
 Portugal 129 0.080 0.42545±0.0069 1.00000±0.0000 
(Oliveira et 
al., 2007a) 
 Romania 332 0.093 0.18419±0.0072 0.60297±0.0074 
(Buzoianu 
et al., 
2012) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.001 
n, sample size 
q, frequencies of the minor allele  
Ref., references 
Continuation of the previous table. 
 
 
Is worthy of note the pattern of frequencies across European, Portuguese Gypsy 
and Indian populations, observed for CYP2C9*2. In the Portuguese Gypsies the 
frequency is intermediate between the European and Indian values (Figure 10). This 
finding may be a signal of the long lasting process of admixture that has characterized 
the history of all Roma groups. A few centuries after having left India, the Roma groups 
arrived in Europe, where they spread into the entire continent through multiple 
dispersion routes, during which strong interactions were established with the host 
populations, as well did when they become established in specific European regions 
(Kalaydjieva et al., 2005). 
 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
 Russia 290 0.067 0.84642±0.0014 0.54268±0.0077 
(Gaikovitc
h et al., 
2003) 
 Slovenia 127 0.063 1.00000±0.0000 0.59735±0.0025 
(Herman 
et al., 
2003) 
 Spain 200 0.062 1.00000±0.0000 0.51289±0.0071 
(Mas et 
al., 2005) 
 Sweden 1490 0.071 0.61582±0.0050 0.70366±0.0068 
(Wadelius 
et al., 
2009) 
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Figure 10. CYP2C9*2 allele frequency distribution of the European, Indian and Gypsy populations. The frequency of the 
Portuguese Gypsy population is represented in blue, the frequency of the Portuguese non-Gyspy population is 
represented in red and the frequency of the Hungarian Roma population is represented in violet.  
 
 
1.2 Cytochrome P450 2C19 – CYP2C19 
 
CYP2C19 is another CYP enzyme that plays a significant role in the activation and 
detoxification of several classes of drugs such as clopidogrel and omeprazole (Zanger 
et al., 2008).  
The CYP2C19*2 is associated with the PM phenotype, which is characterised by an 
absence of enzymatic activity. Interestingly, this CYP2C19 PM phenotype seems to 
have a role in H. pylori eradication therapy, because its administration in conjunction 
with the antibiotics produces, in PM patients compared to other phenotypes, more 
accentuated improvements on the symptoms and on effectiveness of the antibiotics 
(Zanger et al., 2008). 
The allele frequencies of CYP2C19*2 estimated for the Portuguese non-Gypsy and 
Gypsy samples are shown in Table 6. No differences between them were detected 
through the Fisher exact test (p=0.26675±0.0083). 
 
 
 
  
FCUP 56 
A study on Pharmacogenetic polymorphisms in the Portuguese Gypsies 
   
 
Table 6. Allele frequencies of CYP2C19 in the Portuguese non-Gypsy and Gypsy populations. 
 
 
  
 
 
 
 
Comparative analyses were again performed between data here obtained and 
allelic frequencies recruited from the literature, with differences being assessed as 
previously referred, according to the correction for multiple tests (Table 7). The 
frequency of CYP2C19*2 in the Portuguese non-Gypsy reference sample was only 
statistically different from values in Ghana, China, South India and Thailand. On the 
other hand, the frequency of the same allele in the Portuguese Gypsies revealed 
significant differences comparatively to frequencies in some African populations, but in 
contrast, it did not differed from the registered in the majority of Asian and European 
populations. 
In the before mentioned study of Oliveira et al. (2007a), where CYP2C19*2 was 
also screened in a Portuguese sample, the frequency estimate obtained was not 
statistically different from the values here obtained either in Gypsies or non-Gypsies.  
Data available for the Roma group from Hungary (Sipeky et al., 2013), did not 
revealed differences comparatively to the CYP2C19*2 frequency in the Portuguese 
Gypsies, but is of note that both Roma groups present the highest frequencies of 
CYP2C19*2 in populations from Europe. 
In North and South India CYP2C19*2 is very well represented (Lamba et al. (2000) 
and Jose et al. (2005), respectively), reaching frequencies higher than usually found in 
European populations. Comparing the allele frequency in the Portuguese Gypsies with 
that in North India, no statistical difference was found, but on the contrary, when it was 
compared with the frequency in South India, the difference reached statistical 
significance. 
 
 
 
 
 
 
CYP2C19 
Portuguese non-Gypsies 
(n) 
Portuguese Gypsies 
(n)   
CYP2C19*2 0.164±0.031 (70) 0.211±0.027 (116) 
n, sample size 
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Table 7. Comparison of allele frequencies of CYP2C19*2 reported from different ethnic populations. 
Continent Population n  q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 Benin 111 0.130 0.43008±0.0057 0.02567±0.0023* 
(Allabi et 
al., 2003) 
 Egypt 247 0.110 0.10530±0.0040 0.00071±0.0008*
†
 
(Hamdy et 
al., 2002) 
 Ghana 204 0.060 0.00032±0.0001*
†
 0.00000±0.0000*
†
 
(Kudzi et 
al., 2009) 
 South Africa 993 0.160 0.90646±0.0013 0.05003±0.0015 
(Dandara 
et al., 
2011) 
America       
 African-American 108 0.250 0.06503±0.0039 0.35077±0.0052 
(Hamdy et 
al., 2002) 
 Bolivia 778 0.078 0.00132±0.0005* 0.00000±0.0000*
†
 
(Bravo-
Villalta et 
al., 2005) 
 
Colombia 
(Mestizos) 
189 0.087 0.01565±0.0007* 0.00000±0.0000*
†
 
(Isaza et 
al., 2007) 
 
Brazil (African 
descent) 
 99 0.170 0.40362±0.0044 0.90194±0.0025 
(Santos et 
al., 2011) 
 
Brazil 
(Amerindian) 
183 0.104 0.07652±0.0037 0.00022±0.0001*
†
 
(Santos et 
al., 2011) 
 
Brazil (Caucasian 
descent) 
615 0.170 1.00000±0.0000 0.13036±0.0072 
(Santos et 
al., 2011) 
 Brazil (Malutto) 315 0.165 1.00000±0.0000 0.13616±0.0078 
(Santos et 
al., 2011) 
 USA 105 0.129 0.34890±0.0070 0.02489±0.0022* 
(Hamdy et 
al., 2002) 
Asia       
 China 121 0.455 0.00000±0.0000*
†
 0.00000±0.0000*
†
 
(Xiao et 
al., 1997) 
 Iran 150 0.130 0.36399±0.0071 0.01235±0.0015* 
(Azarpira 
et al., 
2010) 
 Japan 265 0.279 0.00651±0.0015* 0.04567±0.0014* 
(Sugimoto 
et al., 
2008) 
 Jordania 158 0.123 0.23683±0.0048 0.00564±0.0007* 
(Yousef et 
al., 2012) 
 Korea 271 0.284 0.00331±0.0005* 0.03807±0.0042* 
(Kim et al., 
2010) 
 Lebanon 161 0.134 0.39725±0.0075 0.01813±0.0021* 
(Djaffar 
Jureidini et 
al., 2011) 
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Continuation of the previous table. 
 
Continent Population n  q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
 Malaysia 142 0.280 0.00707±0.0008* 0.06476±0.0045 
(Yang et 
al., 2004) 
 North India 121 0.297 0.00365±0.0007* 0.03382±0.0025* 
(Sipeky et 
al., 2013) 
 South India 341 0.350 0.00000±0.0000*
†
 0.00000±0.0000*
†
 
(Jose et 
al., 2005) 
 Thailand 121 0.351 0.00010±0.0001*
†
 0.00075±0.0006*
†
 
(Yamada 
et al., 
2001) 
 Turkey 404 0.120 0.16792±0.0067 0.00035±0.0002*
†
 
(Sipeky et 
al., 2013) 
 Vietnam 90 0.236 0.15195±0.0063 0.64068±0.0063 
(Yamada 
et al., 
2001) 
Europe       
 Belgium 121 0.091 0.04630±0.0017* 0.00069±0.0005*
†
 
(Allabi et 
al., 2003) 
 Croatia 200 0.150 0.69008±0.0035 0.06647±0.0043 
(Bozina et 
al., 2003) 
 Denmark 64 0.180 0.75762±0.0037 0.49594±0.0061 
(Bathum 
et al., 
1998) 
 Faroe Islands 311 0.187 0.62184±0.0086 0.43595±0.0163 
(Pedersen 
et al., 
2010) 
 Germany 140 0.150 0.77998±0.0042 0.07895±0.0042 
(Hamdy et 
al., 2002) 
 Greece 283 0.137 0.42378±0.0065 0.01434±0.0016* 
(Arvanitidi
s et al., 
2007) 
 Hungary 370 0.126 0.22115±0.0085 0.00113±0.0005* 
(Sipeky et 
al., 2013) 
 Hungary (Gypsy) 500 0.205 0.31091±0.0060 0.86004±0.0041 
(Sipeky et 
al., 2013) 
 Italy 360 0.111 0.08398±0.0036 0.00009±0.0001*
†
 
(Scordo et 
al., 2004) 
 Norway 328 0.152 0.69624±0.0056 0.03961±0.0040* 
(Pedersen 
et al., 
2010) 
 Portugal 126 0.140 0.54840±0.0057 0.04465±0.0031* 
(Oliveira et 
al., 2007a) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.001 
n, sample size 
q, frequencies of the minor allele  
Ref., references 
Continuation of the previous table. 
 
 
So then, the distribution of the frequencies of CYP2C19*2 in European, Portuguese 
Gypsies and Indian populations, follows the trend observed for CYP2C9*2, as is 
illustrated in the map of the Figure 11, which makes quite clear that both the Roma 
from Hungary and Portugal present CYP2C19*2 frequencies that are in the transition 
between those typical of non-Gypsy Europeans and those typical of Indians. 
 
 
 
 
Continent Population n  q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
       
 Romania 200 0.137 0.48033±0.0074 0.01769±0.0017* 
(Buzoianu 
et al., 
2010) 
 Russia 290 0.114 0.12036±0.0072 0.00031±0.0002*
†
 
(Gaikovitc
h et al., 
2003) 
 Slovenia 127 0.159 0.88272±0.0024 0.13727±0.0067 
(Herman 
et al., 
2003) 
 Spain 177 0.130 0.31563±0.0046 0.01352±0.0027* 
(Arias et 
al., 2005) 
 Sweden 185 0.160 0.89279±0.0023 0.13596±0.0082 
(Ramsjö et 
al., 2010) 
Oceania       
 Australia 99 0.145 0.64714±0.0053 0.10258±0.0068 
(Hoskins 
et al., 
1998) 
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Figure 11. CYP2C19*2 allele frequency distribution of the European, Indian and Gypsy populations. The frequency of 
the Portuguese Gypsy population is represented in blue, the frequency of the Portuguese non-Gypsy population is 
represented in red and the frequency of the Hungarian Roma population is represented in violet. 
 
 
1.3 Thiopurine S-methyltransferase – TPMT 
 
Thiopurine S-methyltransferase (TPMT),  a cytoplasmic enzyme that catalyses the 
methylation of diverse thiopurine drugs, is often considered one of the best models in 
Pharmacogenetics due to its well established relevance in thiopurine chemotherapy 
(Kubota and Chiba, 2001; Krynetski and Evans, 2003). 
The studied SNPs in the gene encoding for this enzyme define alleles TPMT*2, 
TPMT*3A, TPMT*3C and TPMT*8, which together are responsible for the majority of 
deficient methylator phenotypes in most populations, even though presenting 
considerable distribution heterogeneity across major human populations (Oliveira et al., 
2007b; Garat et al., 2008; Roberts and Barclay, 2012). For instance, while TPMT*3A 
prevail in Caucasians, TPMT*3C is the predominant allele in Asian and African 
populations and TPMT*8 has been quite restrictively detected in African populations or 
populations of African descent (Wang et al., 2010). Accordingly, TPMT*3C was not 
detected in this study. Also TPMT*2 was absent from both samples examined, which 
indeed was also not surprising given that TPMT*2 has been demonstrated to be one of 
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the less frequent deficient alleles in most populations where it was identified (McLeod 
et al., 2000). 
Out of the referred 4 TPMT alleles, only TPMT*8 and TPMT*3A were detected in 
this study, and the estimated frequencies in Portuguese non-Gypsies and Gypsies are 
summarised in Table 8.  
 
 
Table 8. Allele frequencies of TPMT in the Portuguese non-Gypsy and Gypsy populations. 
 
 
 
 
 
 
 
          
TPMT*8 was only found in a heterozygous Gypsy individual. On the other hand, 
TPMT*3A was detected in both samples, at the low frequency of 2.9% in the 
Portuguese non-Gypsies and at the very low frequency of 0.4% in the Portuguese 
Gypsies. Neither for TPMT*3A nor for TPMT*8 differences in frequencies between both 
samples were statistically significant (p=0.07144±0.0022 for TPMT*3A and p= 
1.00000±0.0000 for TPMT*8). 
In Tables 9 and 10 are presented the results of the comparative tests performed 
between data here obtained for TPMT*3A and TPMT*8, respectively, and previously 
published frequencies for other populations. 
For TPMT*3A, the frequency of 2.9% in the Portuguese non-Gypsies lies in the 
range of values commonly found in other European populations, where the allele 
presents its peak of frequency at 8.6% in a sample from Germany. In Africa, TPMT*3A 
has only been sporadically detected and in most Asian populations it occurs at very low 
frequency. In line with this overall pattern, the frequency of TPMT*3A in the Portuguese 
non-Gypsies was found to be statically different from the typical values in African and 
many Asian populations assuming the conventional p≤0.05 as level of significance, 
although when corrected for multiple tests only differences with Korea and South India  
maintained statistical significance. As for TPMT*3A in the Portuguese Gypsies, 
differences in frequencies were only significant with Bolivian and German considering 
the correction for multiple tests. 
TPMT 
Portuguese non-Gypsies 
(n) 
Portuguese Gypsies 
(n) 
TPMT*3A 0.029±0.014 (70) 0.004±0.004 (116) 
TPMT*8 0.000±0.000 (70) 0.004±0.004 (116) 
n, sample size 
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For TPMT*8 allele, no differences with statistical significance were found, which 
otherwise is understandable given that this rare deficient allele only reaches 
frequencies around 2% in African populations, and so due to relative rarity it is difficult 
to capture statistical differences. 
Comparing our TPMT data for the Portuguese reference sample with that 
previously published by Alves et al. (2000) and Alves et al. (2001) also for Portugal, a 
strong agreement is observed, despite Alves et al. had additionally detected TPMT*2 at 
the very low frequency of 1.5% in the study of 2000 and 1% in the study of 2001. 
Finally, focusing in the samples from the North and South India studied by Kapoor 
et al. (2009) and Umamaheswaran et al. (2012), respectively, TPMT*3A was not 
detected in South India, whereas in the North its presence is almost residual, 0.04%, 
which coincidentally equals the frequency registered in the Portuguese Gypsies. 
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Table 9. Comparison of allele frequencies of TPMT*3A reported from different ethnic populations. 
 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 African-American 248 0.008 0.07907±0.0024 1.00000±0.0000 
(Hon et al., 
1999) 
 Cabinda 103 0 0.02736±0.0006* 1.00000±0.0000 
(Oliveira et 
al., 2007b) 
 Egypt 200 0.003 0.01674±0.0004* 1.00000±0.0000 
(Hamdy et 
al., 2003) 
 Ghana 217 0 0.00371±0.0004* 0.35011±0.0018 
(Ameyaw et 
al., 1999) 
 Mozambique 250 0.002 0.00957±0.0005* 0.53280±0.0020 
(Alves et al., 
2004) 
America       
 Argentina 147 0.030 1.00000±0.0000 0.04862±0.0014* 
(Laróvere et 
al., 2003) 
 Bolivia 115 0.065 0.14923±0.0035 0.00019±0.0001*
†
 
(Lu et al., 
2005) 
 Brazil 204 0.015 0.28452±0.0030 0.43680±0.0020 
(Boson et 
al., 2003) 
 USA 282 0.032 1.00000±0.0000 0.01926±0.0010* 
(Hon et al., 
1999) 
Asia       
 China 192 0 0.00505±0.0005* 0.37850±0.0015 
(Collie-
Duguid et 
al., 1999) 
 Iran 127 0.008 0.18815±0.0033 1.00000±0.0000 
(Azad et al., 
2009) 
 Japan 151 0 0.01018±0.0006* 0.43493±0.0018 
(Kubota and 
Chiba, 2001) 
 Jordania 169 0.012 0.24070±0.0037 0.65337±0.0024 
(Hakooz et 
al., 2010) 
 Korea 400 0 0.00036±0.0001*
†
 0.22516±0.0024 
(Lee et al., 
2008) 
 North India 120 0.004 0.06549±0.0024 1.00000±0.0000 
(Kapoor et 
al., 2009) 
 South India 608 0 0.00016±0.0001*
†
 0.15892±0.0014 
(Umamahes
waran et al., 
2012) 
 Turkey 148 0.010 0.21646±0.0020 0.63477±0.0014 
(Sayitoglu et 
al., 2006) 
Europe       
 Croatia 350 0.042 0.63597±0.0038 0.00410±0.0007* 
(Kapitanović 
et al., 2006) 
 Denmark 200 0.033 1.00000±0.0000 0.02198±0.0010* 
(Toft et al., 
2006) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.002 
n, sample size 
q, frequencies of the minor allele  
Ref., references 
Continuation of the previous table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
 France 304 0.033 1.00000±0.0000 0.01599±0.0011* 
(Ganiere-
Monteil et 
al., 2004) 
 Germany 1214 0.086 0.00953±0.0012* 0.00000±0.0000*
†
 
(Hakooz et 
al., 2010) 
 Italy 103 0.039 0.76636±0.0016 0.01637±0.0005* 
(Rossi et al., 
2001) 
 Norway 66 0.034 1.00000±0.0000 0.06242±0.0016 
(Hamdy et 
al., 2003) 
 Poland 358 0.027 0.78055±0.0028 0.03703±0.0016* 
(Kurzawski 
et al., 2004) 
 Portugal 143 0.025 0.75567±0.0017 0.07861±0.0020 
(Alves et al., 
2001) 
 Russia 549 0.016 0.30468±0.0032 0.22834±0.0037 
(Samochato
va et al., 
2009) 
 Slovenia 194 0.041 0.60682±0.0039 0.00482±0.0004* 
(Hakooz et 
al., 2010) 
 Spain 105 0.024 1.00000±0.0000 0.10468±0.0021 
(Corominas 
et al., 2003) 
 Sweden 800 0.038 0.81237±0.0027 0.00401±0.0007* 
(Haglund et 
al., 2004) 
 UK 199 0.045 0.47493±0.0053 0.00268±0.0004* 
(Ameyaw et 
al., 1999) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.008 
n, sample size 
q, frequencies of the minor allele 
Ref., references  
Table 10. Comparison of allele frequencies of TPMT*8 reported from different ethnic populations. 
 
 
 
1.4 N-acetyltransferase 2 – NAT2 
 
The NAT2 enzyme that intervenes in many reactions of phase II of the drug 
metabolism plays a relevant function in the acetylation of several xenobiotics and 
therapeutic drugs such as is isoniazid (Bakayev et al., 2004; Teixeira et al., 2013). 
The presence of polymorphisms in NAT2 gene can influence the acetylation 
capacity of the codified enzyme that consequently may alter the activation or 
detoxification of the genotoxic elements, leading to the manifestation of several side 
effects (Bakayev et al., 2004).  
The NAT2 2-SNP genotype panel here used, consisting in the screening of the 
SNPs c.282C>T and c.341T>C, was reported to allow for the inference of the NAT2 
phenotypes with great accuracy, affording a level of precision obtained with the 
conventional 7-SNP genotype panel. This precision is only not achieved for populations 
of African ancestry, because this methodology did not include a SNP, c.191G>A, 
frequently found only in populations from Africa (Cascorbi et al., 1995; Cascorbi and 
Roots, 1999; Selinski et al., 2011). 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 Cabinda 103 0.024 0.08423±0.0017 0.10456±0.0021 
(Oliveira et 
al., 2007b) 
 Mozambique 250 0.016 0.21213±0.0031 0.28666±0.0026 
(Alves et 
al., 2004) 
America       
 African-American 248 0.002 1.00000±0.0000 0.53844±0.0018 
(Hon et 
al., 1999) 
Europe       
 Portugal 150 0.005 1.00000±0.0000 1.00000±0.0000 
(Alves et 
al., 2000) 
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The 2-SNP genotype is the sum of  variant c.282C>T and c.341T>C alleles with the two 
and more variant alleles (2+) correspond to the slow genotype, the one variant alleles 
(1) corresponding to the intermediate genotype and the null variant alleles (0) 
corresponding to the rapid genotype. 
 
Based on these assumptions, the 2-SNP panel was applied to characterise the two 
Portuguese samples in order to infer the acetylation phenotypes, which are presented 
in table 11. 
 
 
Table 11. Frequencies of the slow, intermediate and rapid acetylators in the Portuguese non-Gypsy and Gypsy 
populations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
The frequencies of the slow, intermediate or high acetylators (2+, 1 and 0, 
respectively) were similar in the Portuguese Gypsy and non-Gypsy samples. 
The inferred phenotypic data was used to estimate frequencies of the combined set 
of haplotypes associated to slow and high acetylation capacity, herein referred to for 
simplicity as slow and high haplotypes, which are shown in table 12. Values in Gypsies 
and non-Gypsies were quite similar, and so obviously non-significantly different 
(p>>>>0.05).    
 
 
Table 12. Combined frequency of slow and rapid NAT2 haplotypes. 
  
 
 
 
 
 
                                     
NAT2 
Genotype 
Portuguese non-Gypsies Portuguese Gypsies 
 No. of subjects Frequency No. of subjects Frequency 
2+ 40 0.571 66 0.574 
1 27 0.386 43 0.374 
0 3 0.043 6 0.052 
 
Haplotypes Portuguese non-Gypsies  Portuguese Gypsies    
Slow 0.764±0.036 0.761±0.028 
Rapid 0.236±0.036 0.239±0.028 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.007 
n, sample size 
Ref., references 
 
From previous works that also used the 2-SNP genotype panel to infer the NAT2 
phenotypes, information was compiled to carry on comparisons with the haplotypic 
frequencies obtained in this study (table 13). Up to now, however, data produced with 
this SNP panel was only available for 5 additional populations, which strongly limits the 
comparative analysis. From the existing data we can see that the distribution of slow 
and fast haplotypes is quite homogeneous across populations, including the two 
population samples here analysed. Consequently, no significant differences were 
detected between frequencies in the Portuguese Gypsies and non-Gypsies 
comparatively to any other population. 
 
 
Table 13. Comparison of slow NAT2 haplotypes reported from different ethnic populations. 
 
 
 
 
 
 
 
Continent Population n Slow 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
America       
 
Brazil (White 
Brazilian) 
136 0.779 0.80865±0.0050 0.66750±0.0106 
(Suarez-
Kurtz et al., 
2012) 
 Brazil (Guarani) 88 0.722 0.43757±0.0069 0.42574±0.0124 
(Suarez-
Kurtz et al., 
2012) 
 Venezuela 287 0.731 0.45752±0.0050 0.42480±0.0087 
(Selinski et 
al., 2011) 
Asia       
 Pakistan 163 0.791 0.54524±0.0119 0.40559±0.0066 
(Selinski et 
al., 2011) 
Europe       
 
Hungary plus 
Germany 
2106 0.768 0.91989±0.0024 0.81453±0.0070 
(Selinski et 
al., 2011) 
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1.5 Vitamin k epoxide reductase complex subunit 1 – VKORC1 
 
The VKORC1, an important enzyme in the formation of functional clotting factors, is 
encoded by the recently identified VKORC1 gene (Li et al., 2004). This enzyme is the 
target of many anticoagulant or vitamin k antagonists (VKAs) drugs, such as warfarin, 
inhibiting the synthesis of clotting factors (Yin and Miyata, 2007; D’Andrea et al., 2008; 
Limdi and Veenstra, 2008). 
Many studies have proved that polymorphisms in VKORC1 gene may influence the 
sensibility of the individuals to the VKAs, leading to different responses, as bleeding 
effects or resistance to the therapies. A number of algorithms to adjust the dose 
administrated to each patient have been proposed taking genetic information into 
account (Mushiroda et al., 2006; Yin and Miyata, 2007; Puehringer et al., 2010).  
The selected SNP that was screened in this work, c.-1639G>A, is one of the most 
widely studied SNPs in the VKORC1 gene, due to its well established role in the 
variability  of mRNA level. While the G allele is associated with an increment of 44% in 
the gene transcription activity, the A allele is responsible for the hindrance of binding of 
a transcription factor in the VKORC1 promoter region, decreasing the levels of the 
mature VKORC1 proteins (Sipeky et al., 2009a; Kwon et al., 2011; Smires et al., 2012). 
The allele frequency of the VKORC1 c.-1639G>A in the Portuguese non-Gypsy and 
Portuguese Gypsy populations are described in Table 14. 
 
 
Table 14.  Allele frequencies of VKORC1 c.-1639G>A in the Portuguese non-Gypsy and Gypsy populations. 
 
 
 
 
 
 
 
 
The frequency of the derived allele at c.-1639G>A was high in both populations, 
and although being slightly more elevated in the Portuguese non-Gypsies than in the 
Gypsies, the difference had no statistical significance (p=0.51784±0.0100).  
The estimate now obtained for c.-1639G>A in the reference sample from Portugal 
is very similar to that previously reported by Jorge et al. (2010), which was confirmed 
when differences between values were tested (Table 15).  
VKORC1 
Portuguese non-Gypsies 
(n) 
Portuguese Gypsies 
(n)  
c.-1639G>A 0.443±0.042 (70) 0.404±0.032 (115) 
n, sample size 
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When comparing the frequencies obtained in this study with other retrieved from 
the bibliography (Table 15), we could see that the distribution of c.-1639G>A in the two 
Portuguese samples was in the range of what has been reported for European 
populations. Hence, the absence of significant differences between Portuguese 
Gypsies or non-Gypsies and most other Europeans. The two Portuguese samples also 
did not differ from the majority of African or American populations. In contrast, 
compared to populations from Central and Eastern Asia, where allele A reaches 
frequencies up to 70%, both samples here studied showed highly significant 
differences.  
Respecting to the comparisons with the Hungarian Gypsies studied by Spikey et al. 
(2009a), while both Portuguese Gypsies and non-Gypsies revealed significant 
differences at the conventional p-value, assuming the p adjusted for multiple tests the 
difference involving the Portuguese Gypsies lost significance. 
Nahar et al. (2013) and Gaikwad et al. (2013), had also examined VKORC1 c.-
1639G>A in North and South India, respectively, reporting frequencies that are in the 
lower range of values observed at a worldwide scale. Accordingly, when compared to 
frequencies here estimated for the Portuguese Gypsies and non-Gypsies, all the 
pairwise differences had statistical significance. 
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Table 15. Comparison of allele frequencies of VKORC1 c.-1639G>A reported from different ethnic populations. 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
Africa       
 Egypt 63 0.510 0.32718±0.0081 0.07076±0.0051 
(Bazan et 
al., 2013) 
 Morocco 96 0.271 0.00228±0.0008
*
 0.00611±0.0016
*
 
(Smires et 
al., 2012) 
America       
 African-American 50 0.120 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Wu, 
2007) 
 Argentina 101 0.504 0.27048±0.0049 0.04594±0.0056
*
 
(Scibona 
et al., 
2012) 
 Ashkenazi Jewish 260 0.467 0.63537±0.0113 0.11534±0.0063 
(Scott et 
al., 2008) 
 Sephardi Jewish 80 0.500 0.35136±0.0060 0.06451±0.0068 
(Scott et 
al., 2008) 
 USA 100 0.335 0.05541±0.0044 0.17306±0.0052 
(Babic et 
al., 2009) 
Asia       
 China 178 0.916 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Miao et 
al., 2007) 
 Indonesia 130 0.770 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Suriapran
ata et al., 
2011) 
 Iran 126 0.556 0.03737±0.0053
*
 0.00110±0.0003
*†
 
(Azarpira 
et al., 
2010) 
 Japan 341 0.918 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Yoshizaw
a et al., 
2009) 
 Korea 37 0.945 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Kwon et 
al., 2011) 
 Lebanon 231 0.524 0.10070±0.0075 0.00445±0.0013
*
 
(Esmerian 
et al., 
2011) 
 Malaysia 91 0.736 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Gan et 
al., 2011) 
 North India  209 0.190 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Nahar et 
al., 2013) 
 Saudi Arabia 131 0.427 0.83956±0.0024 0.65138±0.0079 
(Alzahrani 
et al., 
2013) 
 South India 145 0.128 0.00000±0.0000
*†
 0.00000±0.0000
*†
 
(Gaikwad 
et al., 
2013) 
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* Significant value at p≤0.05 
†
 Significant value with Bonferroni correction p<0.002 
n, sample size 
q, frequencies of the minor allele  
Ref., references 
Continuation of the previous table. 
 
 
Highlighting the frequencies for VKORC1 c.-1639G>A in European, Portuguese 
Gypsies and Indian populations, the pattern of differences is consistent, although less 
sharp, with that observed for CYP2C9*2 and CYP2C19*2, indicating that the 
evolutionary history of a population can influence differently each gene (Figure 12). 
 
 
Continent Population n q 
P-value Portuguese 
non-Gypsies 
P-value Portuguese 
Gypsies 
Ref. 
       
 Turkey 292 0.404 0.44316±0.0097 1.00000±0.0000 
(Silan et 
al., 2012) 
Europe       
 France 263 0.420 0.63444±0.0068 0.73965±0.0122 
(Bodin et 
al., 2005) 
 Hungary 510 0.390 0.23282±0.0048 0.70275±0.0040 
(Sipeky et 
al., 2009a) 
 Hungary (Gypsy) 451 0.297 0.00083±0.0001
*†
 0.00237±0.0003
*
 
(Sipeky et 
al., 2009a) 
 Italy 437 0.443 1.00000±0.0000 0.32704±0.0174 
(Zambon 
et al., 
2010) 
 Portugal 91 0.417 0.65522±0.0075 0.84137±0.0046 
(Jorge et 
al., 2010) 
 Romania 332 0.422 0.71697±0.0087 0.69704±0.0078 
(Buzoianu 
et al., 
2012) 
 Russia 111 0.333 0.04773±0.0043
*
 0.12143±0.0087 
(Vorob'eva 
et al., 
2011) 
 Spain 101 0.436 0.91115±0.0026 0.54417±0.0070 
(Scott et 
al., 2010) 
 Sweden 1461 0.394 0.25094±0.0056 0.78772±0.0058 
(Wadelius 
et al., 
2009) 
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Figure 12. VKORC1 c.-1639G>A allele frequency distribution of the European, Indian and Gypsy populations. The 
frequency of the Portuguese Gypsy population is represented in blue, the frequency of the Portuguese non-Gypsy 
population is represented in red and the frequency of the Hungarian Roma population is represented in violet. 
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2. Final considerations 
  
The interindividual and interethnic variability in the response to drugs can be 
influenced by polymorphisms in genes encoding metabolising enzymes (DMEs), 
transporters and targets of the drugs, altering their normal metabolism and effect. 
Thus, the development of the Pharmacogenetic tests can be a helpful tool in the clinical 
practice, because the mobilization of relevant information about the genes and 
polymorphisms that affect the metabolism and effectiveness of drugs, can improve the 
therapeutic protocols.  
In the present study, we have analysed variants in 4 genes coding for distinct 
DMEs and 1 gene that encodes a drug target in Portuguese Gypsy and non-Gypsy 
samples.  
The results obtained, only revealed significant differences between both samples in 
one of the screened variations, which was CYP2C9*2 that occurred at frequency of 
10.8% in Gypsies and 20.0% in non-Gypsies. Within the same locus, the frequency of 
CYP2C9*3 was, however, non-significantly higher in Gypsies than in non-Gypsies, 
implying that for CYP2C9, the combined frequency of alleles associated to decreased 
enzymatic activity attained 18.7% and 25.7% in the Portuguese Gypsies and non-
Gypsies, respectively. This means that in Portugal, Gypsies, comparatively to other 
Portuguese, are slightly less predisposed to develop ADRs for drugs metabolised by 
CYP2C9. Applying the Fisher exact test, the differences observed between the 
combined frequency of alleles in Portuguese Gypsies and non-Gypsies had no 
statistical significance (p= 0.14599±0.0053). 
For the other studied pharmacogenetic polymorphisms, no significant differences 
were detected between Gypsies and other Portuguese. 
As a whole, our findings indicate that from the Pharmacogenetic point of view, the 
Gypsies from Portugal do not raise added concerns comparatively to the host 
population. 
The analysis of pharmacogenetic-related diversity in the Portuguese Gypsies was 
triggered by the previous knowledge that they showed peculiar genetic characteristics 
that distinguish them, as a group, from the Portuguese, in the general sense. 
Furthermore, all Gypsy groups have been subject along history to strong drift effects, 
as is for instance reflected in their fraction of genetic diversity that implies pathogenic 
consequences. In fact, many diseases occur with unusual high prevalence in Roma 
groups, as exemplifies the elevated incidence of Maple Syrup Urine Disease in the 
Portuguese Gypsies (Quental et al., 2009). 
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This justifies the rationale of investigating in the Portuguese Gypsies genetic 
variations known to have pharmacogenetic relevance. For none of the polymorphisms 
examined, the Portuguese Gypsies, comparatively to other Portuguese, appear to need 
a special vigilance care, in the prescription, administration, dosage and maintenance of 
metabolised drugs by the enzymes encoded by the genes studied. 
Obviously, the picture here obtained on the pharmacogenetic profile of the 
Portuguese Gypsies still needs to be improved.  
A critical drawback of this study was to be based on a small number of SNPs for 
each gene, which despite having been selected among the most widely studied SNPs, 
may not represent the adequate SNP coverage for Gypsy groups. In fact, without 
knowing at which extent a given set of screened variations contribute to explain 
variability in levels of enzymatic/proteic activity  in a population, it is difficult  to evaluate 
whether it represent  a good proxy of the set of alleles affecting gene expression in that 
population.  In the case of Gypsies, this might be a key question, due to their shared 
past ancestry in Indian populations, which currently also remain understudied in which 
respect pharmacogenetic polymorphisms. By other words, we cannot exclude that, for 
each of the studied genes, additional variations apart from those examined might 
impact substantially drug response in Gypsies, whilst being irrelevant (due to absence 
or rarity) in other European populations. 
To clarify the issue, enzymatic/proteic activities should be measured in individuals 
from the two populations and then contrasted with the genotypic results obtained 
through a fine gene screening. This would elucidate whether unknown or unstudied 
SNPs have pharmacogenetic consequences in the Portuguese Gypsies, which may be 
rare or absent in the general Portuguese population. 
If the screened variations only encompassed a very small fraction of 
pharmacogenetic polymorphisms, it is noteworthy how they captured signals of the 
history of Portuguese Gypsies. Most of the variations had frequency data for Indian 
populations, which showed values rather different from those typically found in 
European populations, including from Portugal.  For all these variation the Portuguese 
Gyspies presented frequency values between those found in Indians and Portuguese 
non-Gypsies. Despite the absence of a systematic statistical support of the differences, 
the finding is fairly consistent with the inferred genetic origin of the Roma, since strong 
evidence point to India as the region from where departed the first people who, in 
successive waves of migrations, would give rise to the European Roma.  
In Figure 13 is depicted a plot obtained through Principal Component Analysis 
based on frequencies of CYP2C9*2, CYP2C9*3, CYP2C19*2, TPMT*3A and VKORC1 
c.-1639G>A in distinct European and Indian populations. Only samples with data 
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available for the five variations were included in the analysis, explaining the relative 
small number of populations considered. NAT2 and TPMT*8 was excluded because it 
had not been characterized in those populations. 
 
 
 
 
Figure 13. Principal Component Analysis (PCA) based on allelic frequency values between 8 populations (Portugal, 
Spain, Russia, Portuguese Roma, Sweden, Italy, South India, North India) for 5 SNPs. 
 
 
Dimension 1 sharply discriminates Indian from European populations. The Gypsies 
from Portugal are integrated in the cluster of European populations, but among them 
the Gypsies are the group positioned closer to Indian samples, seemly testifying that 
Indians were one of their source populations.  
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V. CONCLUSIONS 
 
 
Many populations of the world have been the subject of the pharmacogenetic 
studies, however there are still population groups poorly studied in this area, as is the 
case of the Gypsy groups. 
Gypsies meet unique genetic characteristics that differentiate them from the host 
populations, making them a very attractive case of study in several areas. 
In this work, several SNPs in genes with pharmacogenetic relevance were 
analysed in a sample of Portuguese Gypsies. Then, the results were compared with 
those respecting to the host population, in order to evaluate whether significant 
differences between the populations existed. 
The obtained results did not demonstrate major differences between the two 
populations for the studied SNPs. Thus, this means that it is not necessary a distinct 
vigilance care in the Portuguese Gypsies in comparison with other Portuguese in the 
administration of drugs whose metabolism or effect depend on the encoded products of 
the studied genes. 
The absence of significant differences between the two populations do not 
necessarily signifies that they have similar pharmacogenetic risks, since it was only 
analysed a small group of genes and SNPs, which may not be enough to bring to light 
unsuspected differences in terms of the expectations on how individuals from each 
population  will respond  to drugs. 
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VI. FUTURE DIRECTIONS 
 
 
In order to obtain a better assessment of differences between Portuguese Gypsies 
and the host population, it should be quantified the activity of the enzymes/proteins 
encoded by the selected genes and contrast the information with genotypic data. 
Preferably complete sequencing of the genes should be performed, which would allow 
for the detection of new SNPs in the Portuguese Gypsies that might be of 
pharmacogenetical significance. In addition, other genes and SNPs known to affect   
drug response should be studied and compared in both samples. 
 It would be also important to investigate thoroughly other Gypsy groups from all 
around the world, thus allowing a better understanding of their pharmacogenetic 
profiles, once none Gypsy group can be representative of other Gypsies groups. 
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VIII. ANNEXES 
 
Annex 1. Supplementary data for the ten loci studied. 
 
 
 
 
 
 
 
 Portuguese non-Gypsies Portuguese Gypsies 
Locus Ho He P-value Ho He P-value 
c.238G>C Monomorphic locus Monomorphic locus 
c.460G>A 0.05714 0.05591 1.00000±0.00000 0.00862 0.00862 1.00000±0.00000 
c.719A>G 0.05744 0.05591 1.00000±0.00000 0.00862 0.00862 1.00000±0.00000 
c.664G>A Monomorphic locus 0.00862 0.00862 1.00000±0.00000 
c.430C>T 0.31429 0.32230 1.00000±0.00000 0.18103 0.19313 0.61789±0.00050 
c.1075A>C 0.11429 0.10853 1.00000±0.00000 0.15789 0.14607 1.00000±0.00000 
c.681G>A 0.3000 0.27657 0.67627±0.00047 0.30172 0.33464 0.27913±0.00044 
c.282C>T 0.45714 0.42302 0.57576±0.00050 0.42609 0.49474 0.18493±0.00041 
c.341T>C 0.44286 0.50103 0.34618±0.00050 0.38261 0.43835 0.20270±0.00039 
c.-1639G>A 0.48571 0.49702 1.00000±0.00000 0.47826 0.48380 1.00000±0.00000 
He, Expected Heterozygosity 
Ho, Observed Heterozygosity 
